<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7731389</article-id><article-id pub-id-type="pmid">33260759</article-id><article-id pub-id-type="doi">10.3390/ijms21239049</article-id><article-id pub-id-type="publisher-id">ijms-21-09049</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Natural Salicylates and Their Roles in Human Health</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yeasmin</surname><given-names>Fatema</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6049-4426</contrib-id><name><surname>Choi</surname><given-names>Hyong Woo</given-names></name><xref rid="c1-ijms-21-09049" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-ijms-21-09049">Department of Plant Medicals, Andong National University, Andong 36729, Korea; <email>fatema.setudu@gmail.com</email></aff><author-notes><corresp id="c1-ijms-21-09049"><label>*</label>Correspondence: <email>hwchoi@anu.ac.kr</email></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>11</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2020</year></pub-date><volume>21</volume><issue>23</issue><elocation-id>9049</elocation-id><history><date date-type="received"><day>31</day><month>10</month><year>2020</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Salicylic acid (SA) is a plant hormone which plays a crucial role in the plant defense against various pathogens and abiotic stresses. Increasing reports suggest that this phenolic compound and its derivatives, collectively termed salicylates, not only regulate plant defense but also have beneficial effects on human health. Both natural and synthetic salicylates are known to have multiple targets in humans, thereby exhibiting various appreciating pharmacological roles, including anti-inflammatory, anticancer, neuroprotective, antidiabetic effects, and so on. The role of some salicylates, such as acetylsalicylic acid (aspirin), 5-aminosalicylic acid (mesalazine), and amorfrutins in human diseases has been well studied in vitro. However, their clinical significance in different diseases is largely unknown. Based on recent studies, five natural salicylates, including amorfrutin, ginkgolic acid, grifolic acid, tetrahydrocannabinolic acid, and cannabidiolic acid, showed potential roles in different challenging human diseases. This review summarizes together some of the recent information on multitarget regulatory activities of these natural salicylates and their pharmacological roles in human health.</p></abstract><kwd-group><kwd>salicylates</kwd><kwd>pharmacological role</kwd><kwd>amorfrutin</kwd><kwd>ginkgolic acid</kwd><kwd>grifolic acid</kwd><kwd>tetrahydrocannabinolic acid</kwd><kwd>cannabidiolic acid</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-21-09049"><title>1. Introduction</title><p>Traditionally, plants with a high level of salicylates have been used therapeutically throughout the world. Nowadays, salicylates containing plants are used as substitutes for nonsteroidal anti-inflammatory drugs (NSAIDs). In the fourth century B.C., the father of medicine Hippocrates reportedly prescribed extracts of willow leaves or barks to reduce fever and pain during childbirth [<xref rid="B1-ijms-21-09049" ref-type="bibr">1</xref>]. In 1828, the active ingredient salicin (SA derivative) of the willow tree was isolated which is known to be converted to SA upon ingestion. Another natural salicylate methyl salicylate (MeSA), which is found in wintergreen, birch tree, mango, meadowsweet, guelder-rose, is used as analgesic medicine (for joint and muscular pain) and fragrance [<xref rid="B2-ijms-21-09049" ref-type="bibr">2</xref>,<xref rid="B3-ijms-21-09049" ref-type="bibr">3</xref>,<xref rid="B4-ijms-21-09049" ref-type="bibr">4</xref>,<xref rid="B5-ijms-21-09049" ref-type="bibr">5</xref>,<xref rid="B6-ijms-21-09049" ref-type="bibr">6</xref>]. In the middle of the nineteenth century, an intense increase in the medicinal use of SA occurred due to the identification of salicin from willow plants as an anti-inflammatory compound. For growing demand, synthetic SA production was begun commercially in 1874. The most commonly used and recognized salicylate is aspirin (acetyl SA), which was first synthesized by Bayer in 1897. SA had some negative side effects, such as stomach irritation and bleeding, thus it was replaced with aspirin with fewer side effects [<xref rid="B7-ijms-21-09049" ref-type="bibr">7</xref>]. Recent studies suggest that Aspirin not only reduces fever, inflammation, and pain but also reduces the risk of stroke, heart attack, and some type of cancers [<xref rid="B8-ijms-21-09049" ref-type="bibr">8</xref>,<xref rid="B9-ijms-21-09049" ref-type="bibr">9</xref>,<xref rid="B10-ijms-21-09049" ref-type="bibr">10</xref>]. The mechanism of analgesia occurred by aspirin involves the suppression of prostaglandin synthesis by irreversible inhibition of the cyclooxygenases COX1 and COX2 [<xref rid="B11-ijms-21-09049" ref-type="bibr">11</xref>]. Aspirin is also known to target other human proteins, such as nuclear factor-kappaB (NF-&#x003ba;B), cathepsin A (CTSA), ribosomal S6 kinase 2 (RSK2), and cyclin-dependent kinase 2 (CDK2) [<xref rid="B12-ijms-21-09049" ref-type="bibr">12</xref>,<xref rid="B13-ijms-21-09049" ref-type="bibr">13</xref>,<xref rid="B14-ijms-21-09049" ref-type="bibr">14</xref>]. Both natural and synthetic salicylates have beneficial effects for the treatments of different diseases as salicylates can target different human proteins (<xref rid="ijms-21-09049-t001" ref-type="table">Table 1</xref>). For example, 5-aminosalicylic acid targets arachidonate 5-lipoxygenase (ALOX5) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) protein [<xref rid="B15-ijms-21-09049" ref-type="bibr">15</xref>,<xref rid="B16-ijms-21-09049" ref-type="bibr">16</xref>]; Sulfasalazine targets ALOX5 and tumor necrosis factor (TNF&#x003b1;) protein [<xref rid="B15-ijms-21-09049" ref-type="bibr">15</xref>,<xref rid="B17-ijms-21-09049" ref-type="bibr">17</xref>]; Sodium salicylate targets COX2 and NF-&#x003ba;B [<xref rid="B18-ijms-21-09049" ref-type="bibr">18</xref>]; GAPDH and High mobility group box 1 (HMGB1) both are targeted by acetyl 3-aminoethyl salicylic acid [<xref rid="B16-ijms-21-09049" ref-type="bibr">16</xref>,<xref rid="B19-ijms-21-09049" ref-type="bibr">19</xref>]. Thus, salicylates play an important role as a pharmacological agent in human health.</p><p>In this review, we focus on some natural salicylates, amorfrutin, ginkgolic acid, grifolic acid, tetrahydrocannabinolic acid, and cannabidiolic acid and discuss their multitarget inhibitory activities and pharmacological role in human disease (<xref ref-type="fig" rid="ijms-21-09049-f001">Figure 1</xref>). Amorfrutins are natural salicylates isolated from <italic>Amorpha fruticosa</italic> [<xref rid="B25-ijms-21-09049" ref-type="bibr">25</xref>] and <italic>Glycyrrhiza foetida</italic> [<xref rid="B26-ijms-21-09049" ref-type="bibr">26</xref>]. Different types of amorfrutins (A-D) are identified [<xref rid="B27-ijms-21-09049" ref-type="bibr">27</xref>]. These amorfrutins are involved in many biological activities thus increasing the interest on it. The phenolic compound ginkgolic acids are found in leaves and fruits of <italic>Ginkgo biloba</italic> [<xref rid="B28-ijms-21-09049" ref-type="bibr">28</xref>]. These are chemically 2-hydroxy-6-alkylbenzoic acids. Different ginkgolic acids structure such as C13:0, C15:1, and C17:1 have been designated according to their alkyl chain carbon number [<xref rid="B29-ijms-21-09049" ref-type="bibr">29</xref>]. Recent studies suggest that ginkgolic acids have an anticancer property and some other pharmacological role so this compound may be a good target for drug development in human disease. The natural salicylate grifolic acid is isolated from the fruiting bodies of <italic>Albatrellus confluens</italic> fungus and this compound is a derivative of grifolin [<xref rid="B30-ijms-21-09049" ref-type="bibr">30</xref>]. Grifolin shows anticancer activity in different types of cancer by inducing apoptosis and arrest of cell growth [<xref rid="B31-ijms-21-09049" ref-type="bibr">31</xref>,<xref rid="B32-ijms-21-09049" ref-type="bibr">32</xref>,<xref rid="B33-ijms-21-09049" ref-type="bibr">33</xref>,<xref rid="B34-ijms-21-09049" ref-type="bibr">34</xref>,<xref rid="B35-ijms-21-09049" ref-type="bibr">35</xref>]. Some research suggests that grifolic acid also has anticancer activity [<xref rid="B30-ijms-21-09049" ref-type="bibr">30</xref>,<xref rid="B36-ijms-21-09049" ref-type="bibr">36</xref>]. <italic>Cannabis sativa</italic> L. is a medicinal plant that is rich in cannabinoids [<xref rid="B37-ijms-21-09049" ref-type="bibr">37</xref>]. &#x00394;<sup>9</sup>-tetrahydrocannabinolic acid (&#x00394;<sup>9</sup>-THCA) and cannabidiolic acid (CBDA) are the most abundant cannabinoids in <italic>C. sativa</italic> L. and these are the acidic form of &#x00394;<sup>9</sup>-THC and CBD respectively [<xref rid="B38-ijms-21-09049" ref-type="bibr">38</xref>,<xref rid="B39-ijms-21-09049" ref-type="bibr">39</xref>]. Besides the popular cannabinoids (THC and CBD), recently the other cannabinoids like &#x00394;<sup>9</sup>-THCA and CBDA are gaining attention and interest from researchers due to their biological activities.</p></sec><sec id="sec2-ijms-21-09049"><title>2. Pharmacological Roles of Natural Salicylates with Targets</title><sec id="sec2dot1-ijms-21-09049"><title>2.1. Amorfrutins</title><p>Recent studies indicate that amorfrutins show various pharmacological effects including antidiabetic [<xref rid="B40-ijms-21-09049" ref-type="bibr">40</xref>,<xref rid="B41-ijms-21-09049" ref-type="bibr">41</xref>], anticancer [<xref rid="B28-ijms-21-09049" ref-type="bibr">28</xref>], and anti-inflammatory [<xref rid="B42-ijms-21-09049" ref-type="bibr">42</xref>] activities (<xref rid="ijms-21-09049-t002" ref-type="table">Table 2</xref>).</p><sec id="sec2dot1dot1-ijms-21-09049"><title>2.1.1. Antidiabetic Property</title><p>Type-2 diabetes is a worldwide increasing metabolic disease. For its prevention and treatment, new strategies are needed to develop. The gene expression of metabolism, inflammation, and other pathways in adipocytes is mainly regulated by the nuclear receptor PPAR&#x003b3; (peroxisome proliferator-activated receptor gamma) [<xref rid="B73-ijms-21-09049" ref-type="bibr">73</xref>]. Weidner et al. suggest that amorfrutins perform as selective PPAR&#x003b3; modulators (SPPAR&#x003b3;Ms) which increase favorable changes in glucose metabolism and lipid profiles. Amorfrutins were isolated from the edible roots of licorice <italic>G. foetida</italic> and from the fruit of another legume <italic>A. fruticosa</italic> which is used as an ingredient in some condiments. In a competitive time-resolved fluorescent resonance energy transfer (TR-FRET) assay, the four amorfrutins showed the distinct Ki values selectivity for PPAR&#x003b3; subtypes (range from 236 to 354 nM), compared to other PPAR subtypes. Amorfrutins can regulate PPAR&#x003b3; gene expression selectively in adipocytes. Evaluation of in vivo effects in Type 2 diabetes mouse model suggested that amorfrutins act as antidiabetic agent [<xref rid="B40-ijms-21-09049" ref-type="bibr">40</xref>]. Amorfrutin A and B inhibit insulin resistance formation, dyslipidemia, and liver steatosis through activation of PPAR&#x003b3; via ser273 phosphorylation [<xref rid="B40-ijms-21-09049" ref-type="bibr">40</xref>,<xref rid="B41-ijms-21-09049" ref-type="bibr">41</xref>,<xref rid="B43-ijms-21-09049" ref-type="bibr">43</xref>]. These experiments together suggest that selective PPAR&#x003b3;-activation by dietary amorfrutins can develop a promising approach to fight against type-2 diabetes.</p></sec><sec id="sec2dot1dot2-ijms-21-09049"><title>2.1.2. Anticancer Activity</title><p>Today, cancer is a global concern, because of its leading position of causing death with about 8.8 million deaths and 18 million new cases per year [<xref rid="B74-ijms-21-09049" ref-type="bibr">74</xref>,<xref rid="B75-ijms-21-09049" ref-type="bibr">75</xref>]. Many different chemotherapeutic treatments are used for cancer, but those have some toxic side effects [<xref rid="B76-ijms-21-09049" ref-type="bibr">76</xref>], so it is urgent to develop new promising anticancer agents. As an alternative approach, the clinical use of natural products or their synthetic analogs is considered to develop anticancer agents [<xref rid="B77-ijms-21-09049" ref-type="bibr">77</xref>,<xref rid="B78-ijms-21-09049" ref-type="bibr">78</xref>]. A recent study on amorfrutin C shows that it acts as an anticancer agent by inducing apoptosis and inhibiting proliferation of different cancer cell lines, including human colorectal cancer cells (HT-29 and T84), prostate cancer (PC-3), and breast cancer (MCF7) cells (IC<sub>50</sub> values ranging from 8 to 16 &#x003bc;M in these cancer cell lines) through targeting mitochondria. Treatment of HT-29 cells with amorfrutin C induced apoptotic cell death accompanied by the formation of reactive oxygen species, DNA fragmentation, caspase activation, phosphatidylserine externalization, and poly (ADP-ribose) polymerase (PARP) cleavage. Synergistic apoptosis induction of amorfrutin C with alpha Fas receptor ligand (<italic>&#x003b1;</italic>FAS) and TNF-related apoptosis inducing ligand (TRAIL) in HT-29 cells suggest the stimulation of death receptor signaling pathway [<xref rid="B28-ijms-21-09049" ref-type="bibr">28</xref>]. Taken together, amorfrutin C represents a promising candidate for anticancer drug development; however, its cellular target is not clearly identified.</p></sec><sec id="sec2dot1dot3-ijms-21-09049"><title>2.1.3. Anti-Inflammatory Effect</title><p>Although amorfrutin&#x02019;s target PPAR&#x003b3; is the key regulator in metabolic regulation, it can inhibit inflammatory gene expression by a different mechanism including (i) direct interaction with transcription factor NF-&#x003ba;B, (ii) regulation of mitogen-activated protein kinase (MAPK) pathway by reducing p38 activation [<xref rid="B79-ijms-21-09049" ref-type="bibr">79</xref>], (iii) suppression of inflammatory genes expression via SUMOylation-dependent pathway [<xref rid="B80-ijms-21-09049" ref-type="bibr">80</xref>], and (iv) activating E3 ubiquitin ligase activity of PPAR&#x003b3; [<xref rid="B81-ijms-21-09049" ref-type="bibr">81</xref>]. So, for the treatment of inflammatory disease, many clinical studies have been developed to evaluate the anti-inflammatory activity of PPAR&#x003b3; ligands. Amorfrutin A treatment in TNF-&#x003b1;- stimulated colon cells resulted in lower expression of various proinflammatory genes such as <italic>COX-2</italic>, <italic>GRO-&#x003b1;</italic>, <italic>IL-8</italic>, and <italic>MIP-3&#x003b1;</italic> suggesting that amorfrutins may have a beneficial effect for inflammatory disease, such as ulcerative colitis, via targeting PPAR&#x003b3; [<xref rid="B42-ijms-21-09049" ref-type="bibr">42</xref>].</p></sec></sec><sec id="sec2dot2-ijms-21-09049"><title>2.2. Ginkgolic Acids</title><p>Some recent studies suggest that ginkgolic acid (GA) may have a good candidate for developing a drug in different human diseases targeting various proteins. Its pharmacological role includes anticancer activity [<xref rid="B44-ijms-21-09049" ref-type="bibr">44</xref>,<xref rid="B45-ijms-21-09049" ref-type="bibr">45</xref>,<xref rid="B46-ijms-21-09049" ref-type="bibr">46</xref>,<xref rid="B47-ijms-21-09049" ref-type="bibr">47</xref>,<xref rid="B48-ijms-21-09049" ref-type="bibr">48</xref>,<xref rid="B49-ijms-21-09049" ref-type="bibr">49</xref>,<xref rid="B50-ijms-21-09049" ref-type="bibr">50</xref>,<xref rid="B51-ijms-21-09049" ref-type="bibr">51</xref>,<xref rid="B82-ijms-21-09049" ref-type="bibr">82</xref>,<xref rid="B83-ijms-21-09049" ref-type="bibr">83</xref>], neuroprotective role [<xref rid="B52-ijms-21-09049" ref-type="bibr">52</xref>,<xref rid="B53-ijms-21-09049" ref-type="bibr">53</xref>], and antimicrobial activity [<xref rid="B54-ijms-21-09049" ref-type="bibr">54</xref>,<xref rid="B55-ijms-21-09049" ref-type="bibr">55</xref>,<xref rid="B84-ijms-21-09049" ref-type="bibr">84</xref>] (<xref rid="ijms-21-09049-t002" ref-type="table">Table 2</xref>).</p><sec id="sec2dot2dot1-ijms-21-09049"><title>2.2.1. Anticancer Activity</title><p>GA inhibited the proliferation of human Hep-2 cancer cells with the IC<sub>50</sub> value of 20 &#x000b5;M [<xref rid="B82-ijms-21-09049" ref-type="bibr">82</xref>] and induced cell death in human hepatoblastoma HepG2 cells via inducing apoptosis, autophagy, and mitochondrial dysfunction [<xref rid="B51-ijms-21-09049" ref-type="bibr">51</xref>]. Bcl-2 is an antiapoptotic protein located in the outer membrane of mitochondria and plays its role by inhibiting cytochrome release and also caspase-3 activity; on the other hand, the proapototic protein Bax helps to release cytochrome and stimulates caspase-mediated cell death. So, lowering the Bcl-2/Bax ratio can be a good target for anticancer drug development [<xref rid="B85-ijms-21-09049" ref-type="bibr">85</xref>,<xref rid="B86-ijms-21-09049" ref-type="bibr">86</xref>,<xref rid="B87-ijms-21-09049" ref-type="bibr">87</xref>,<xref rid="B88-ijms-21-09049" ref-type="bibr">88</xref>,<xref rid="B89-ijms-21-09049" ref-type="bibr">89</xref>]. Human Hep-2 cells and Tac8113 cells (human tongue squamous carcinoma cell line) treated by GA showed that reduced the Bcl-2/Bax ratio, and enhanced caspase-3 activity. GA also inhibited the growth of Tac8113 cells in a time- and dose-dependent manner with the IC<sub>50</sub> value of 40 &#x000b5;M [<xref rid="B50-ijms-21-09049" ref-type="bibr">50</xref>]. Oncogenic transcription factor STAT3 (Signal transducer and activator of transcription 3) involves in the development of hematological malignancies in multiple myeloma. Phosphorylation of STAT3 stimulates different cancer related proteins, such as Bcl-xl, Bcl-2 (tumorigenesis), Cyclin D1 (proliferation), MMP-9 (invasion), and VEGF (angiogenesis) [<xref rid="B90-ijms-21-09049" ref-type="bibr">90</xref>,<xref rid="B91-ijms-21-09049" ref-type="bibr">91</xref>,<xref rid="B92-ijms-21-09049" ref-type="bibr">92</xref>]. Different tyrosine kinase called janus-like kinase (JAK), including JAK1, JAK2, JAK3, and TYK2 positively regulates the STAT3 pathway [<xref rid="B93-ijms-21-09049" ref-type="bibr">93</xref>,<xref rid="B94-ijms-21-09049" ref-type="bibr">94</xref>]; on the other hand, different protein tyrosine phosphatases (PTPs), including PTEN and SHP-1, negatively regulate STAT3 activation [<xref rid="B95-ijms-21-09049" ref-type="bibr">95</xref>,<xref rid="B96-ijms-21-09049" ref-type="bibr">96</xref>]. Thus, recent studies have been focused on the suppression of STAT3 activity for cancer treatment. Ginkgolic acid C (GAC) 17:1 suppressed STAT3 phosphorylation in multiple myeloma U266 cells and significantly reduced cell proliferation in both U266 and MM.1S cells in a dose- and time-dependent manner. GAC 17:1 upregulated the expression of PTEN and SHP-1 in protein and mRNA level, whereas it down-regulated the expression of STAT3-regulated gene products, such as Bcl-2, Bcl-xL, survivin, IAP-1, COX-2, cyclin D1, VEGF, MMP-9, and MMP-2, in multiple myeloma cells [<xref rid="B49-ijms-21-09049" ref-type="bibr">49</xref>]. In SW480 colon cancer cells, GA treatment inhibited proliferation, migration, and invasion by stimulating adenosine monophosphate activated protein kinase (AMPK) activation and decreasing the expression of invasion-associated proteins such as matrix metalloproteinase-2 (MMP-2), C-X-C chemokine receptor type 4 (CXCR4), and urinary-type plasminogen activator (uPA) [<xref rid="B48-ijms-21-09049" ref-type="bibr">48</xref>]. In lung cancer cells, GA treatment ameliorated migration and invasion by inhibition of the PI3K/Akt/mTOR signaling pathway [<xref rid="B46-ijms-21-09049" ref-type="bibr">46</xref>]. GA reduced the viability of pancreatic cancer cells Panc-1 and BxPC-3. Both in vitro and in vivo results suggested that GA prevented the de novo lipogenesis of pancreatic cancer cells by inducing the activation of AMPK signaling pathway and suppressed several key enzymes (e.g., acetyl-CoA carboxylase [ACC], fatty acid synthase [FASN]) expression involved in lipogenesis [<xref rid="B47-ijms-21-09049" ref-type="bibr">47</xref>]. In MCF-7 and MDA-MB 231 breast cancer cells, GA treatment showed antimigratory effects and inhibited the sumoylation of NEMO leading to inhibition of I&#x003ba;B&#x003b1; degradation. Consequently, reduced activity of NF-&#x003ba;B leads to the downregulation of NF-&#x003ba;B target genes, uPA, plasminogen activator inhibitor-1 (PAI-1), CXCR4, and MMP-9 [<xref rid="B45-ijms-21-09049" ref-type="bibr">45</xref>]. GA inhibited the proliferation of renal cell carcinoma (RCC) cell lines 786-O and A498 by inactivating the epidermal growth factor receptor (EGFR) signaling pathway with the downregulation of p-Akt and p-Erk expression. Thus, GA targets different signaling pathways, including STAT3 pathway, PI3K/Akt/mTOR signaling pathway, and EGFR signaling pathway and causes downregulation of their associated proteins [<xref rid="B44-ijms-21-09049" ref-type="bibr">44</xref>]. Microsomal prostaglandin E2 synthase-1 (mPGES-1)-derived prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) and leukotrienes (LTs) are both crucial mediators in the development of inflammation-associated cancer. GA inhibited the activity of mPGES-1 (IC<sub>50</sub> = 0.7 &#x000b5;M) and 5-lipoxygenase (IC<sub>50</sub> = 0.2 &#x000b5;M), the key enzyme in LT biosynthesis [<xref rid="B83-ijms-21-09049" ref-type="bibr">83</xref>]. So, GA can be an efficient target for developing cancer treatment.</p></sec><sec id="sec2dot2dot2-ijms-21-09049"><title>2.2.2. Neuroprotective Activity</title><p>The aberrant SUMOylation process has been involved in neurodegenerative diseases [<xref rid="B97-ijms-21-09049" ref-type="bibr">97</xref>]. GA directly binds SUMO-activating enzyme (E1) and inhibits the formation of E1-SUMO intermediate [<xref rid="B53-ijms-21-09049" ref-type="bibr">53</xref>]. Neurodegenerative disorder Alzheimer&#x02019;s disease (AD) is identified by the continuous loss of neurons, deposition of insoluble aggregates of two proteins in the brain, amyloid-&#x003b2; (A&#x003b2;) and the microtubule-associated protein tau (MAPT). Synaptic impairment occurs in this disease affecting the hippocampus and entorhinal cortex brain areas thus, hampered cognitive process and memory formation [<xref rid="B98-ijms-21-09049" ref-type="bibr">98</xref>,<xref rid="B99-ijms-21-09049" ref-type="bibr">99</xref>]. GA enhanced long-term potentiation (LTP) in the hippocampus, restored A&#x003b2;-mediated paired-pulse ratio (PPR) alteration, and rescued A&#x003b2;-mediated change in excitatory neurotransmission. The neuroprotective role of GA against A&#x003b2;-induced synaptic deterioration representing an effective approach to AD treatment [<xref rid="B52-ijms-21-09049" ref-type="bibr">52</xref>].</p></sec><sec id="sec2dot2dot3-ijms-21-09049"><title>2.2.3. Antiviral Activity</title><p>HIV-1 protease plays an important role in the HIV viral life cycle as it breaks down the newly synthesized polyproteins to create the mature proteins of an HIV virion. Thus, HIV protease inhibitors (PIs) are very effective antiviral drugs that can reduce the morbidity and mortality of AIDS patients, thus significantly prolong their life [<xref rid="B100-ijms-21-09049" ref-type="bibr">100</xref>]. GA inhibited HIV protease activity in a concentration-dependent manner with the IC<sub>50</sub> of fewer than 30 &#x003bc;g/mL in the cell-free system and inhibited HIV-1SF162 infection in human peripheral blood mononuclear cells (PBMCs) in a concentration-dependent manner (50 and 100 &#x003bc;g/mL) [<xref rid="B54-ijms-21-09049" ref-type="bibr">54</xref>]. GA showed an inhibitory effect on the fusion of a variety of enveloped viruses, including Zika virus (ZIKV), Herpes simplex virus type 1 (HSV-1), human cytomegalovirus (HCMV), human immune deficiency virus (HIV), Ebola virus (EBOV), influenza A virus (IAV), and Epstein Barr virus (EBV) and also inhibited a nonenveloped human adenovirus. In the case of postinfection, GA inhibited HSV-1 and CMV replication targeting protein and DNA synthesis by a secondary mechanism [<xref rid="B55-ijms-21-09049" ref-type="bibr">55</xref>]. GA targets HIV protease enzyme and viral polymerase gene. As a PI, GA can play an important role in antiviral drug development.</p></sec></sec><sec id="sec2dot3-ijms-21-09049"><title>2.3. Grifolic Acids</title><p>Grifolic acid is isolated from the fruiting bodies of <italic>A. confluens</italic> fungus and this compound is a derivative of grifolin [<xref rid="B30-ijms-21-09049" ref-type="bibr">30</xref>]. This grifolin has anticancer properties [<xref rid="B31-ijms-21-09049" ref-type="bibr">31</xref>,<xref rid="B32-ijms-21-09049" ref-type="bibr">32</xref>,<xref rid="B33-ijms-21-09049" ref-type="bibr">33</xref>,<xref rid="B34-ijms-21-09049" ref-type="bibr">34</xref>,<xref rid="B35-ijms-21-09049" ref-type="bibr">35</xref>]. Its acidic form grifolic acid is shown to have anticancer activity [<xref rid="B30-ijms-21-09049" ref-type="bibr">30</xref>,<xref rid="B36-ijms-21-09049" ref-type="bibr">36</xref>] (<xref rid="ijms-21-09049-t002" ref-type="table">Table 2</xref>).</p><sec><title>Antitumor Activity</title><p>Grifolic acid treatment reduced cell viability on GH3 cells, the rat anterior pituitary adenoma cells, in a dose- and time-dependent manner (from 2.5 &#x003bc;M to 20 &#x003bc;M) and resulted in total cell death after 6h treatment with 20 &#x003bc;M. Mitochondrial membrane potential (MMP) production was significantly decreased by grifolic acid (20 &#x003bc;M) 5 min after incubation and caused the maximal effect in 20 min. Grifolic acid also significantly decreased the cellular ATP level in GH3 cells. Without G-protein coupled receptor 120 (GPR120) activity, grifolic acid reduced GH3 adenoma cell viability by blocking NADH production in mitochondria, thereby decreasing MMP and ATP production [<xref rid="B36-ijms-21-09049" ref-type="bibr">36</xref>]. Another report showed almost the same mechanism of grifolic acid in the case of osteosarcoma cell death. Grifolic acid treatment reduced cell viability in a time- and dose-dependent manner on four osteosarcoma cell lines U-2 OS, MG-63, Saos-2, and 143B. Total cell death occurred 6 h after treatment with 30 &#x003bc;M grifolic acid. In the animal model, intratumoral injection of grifolic acid increased necrosis of human osteosarcoma xenograft in nude mice without any observable toxicity [<xref rid="B30-ijms-21-09049" ref-type="bibr">30</xref>].</p></sec></sec><sec id="sec2dot4-ijms-21-09049"><title>2.4. Tetrahydrocannabinolic Acid (THCA) and Cannabidiolic Acid (CBDA)</title><p>The acidic forms of THC and CBD are THCA and CBDA, respectively, and these are the most abundant cannabinoids in <italic>C. sativa</italic> L. [<xref rid="B39-ijms-21-09049" ref-type="bibr">39</xref>]. Based on recent studies, two phytocannabinoids THCA and CBDA may be a good candidate for developing an efficient drug for different human diseases treatment. The pharmacological role of THCA including immunomodulatory effect [<xref rid="B56-ijms-21-09049" ref-type="bibr">56</xref>], anti-inflammatory role [<xref rid="B57-ijms-21-09049" ref-type="bibr">57</xref>,<xref rid="B58-ijms-21-09049" ref-type="bibr">58</xref>], neuroprotective role [<xref rid="B59-ijms-21-09049" ref-type="bibr">59</xref>,<xref rid="B60-ijms-21-09049" ref-type="bibr">60</xref>], and antineoplastic activity [<xref rid="B61-ijms-21-09049" ref-type="bibr">61</xref>,<xref rid="B62-ijms-21-09049" ref-type="bibr">62</xref>].</p><p>Based on in silico analysis, the drug likeness score of CBDA predicted it as possible G protein-coupled receptors (GPCRs) ligands, ion channel modulators, kinase inhibitors, nuclear receptor ligands, and protease inhibitors with moderately active in all bioactive scores [<xref rid="B101-ijms-21-09049" ref-type="bibr">101</xref>]. According to recent studies CBDA has anticancer activity [<xref rid="B63-ijms-21-09049" ref-type="bibr">63</xref>,<xref rid="B64-ijms-21-09049" ref-type="bibr">64</xref>,<xref rid="B65-ijms-21-09049" ref-type="bibr">65</xref>,<xref rid="B66-ijms-21-09049" ref-type="bibr">66</xref>], anti-inflammatory activity [<xref rid="B67-ijms-21-09049" ref-type="bibr">67</xref>,<xref rid="B68-ijms-21-09049" ref-type="bibr">68</xref>,<xref rid="B69-ijms-21-09049" ref-type="bibr">69</xref>], antiemetic effect [<xref rid="B70-ijms-21-09049" ref-type="bibr">70</xref>,<xref rid="B71-ijms-21-09049" ref-type="bibr">71</xref>], and anticonvulsant effect [<xref rid="B72-ijms-21-09049" ref-type="bibr">72</xref>]. Due to its pharmacological property (<xref rid="ijms-21-09049-t002" ref-type="table">Table 2</xref>), it is getting more and more attention.</p><sec id="sec2dot4dot1-ijms-21-09049"><title>2.4.1. Immunomodulatory Effect</title><p>The cannabinoid receptor CB1 and CB2 are involved in immunomodulating actions of cannabinoids [<xref rid="B102-ijms-21-09049" ref-type="bibr">102</xref>,<xref rid="B103-ijms-21-09049" ref-type="bibr">103</xref>,<xref rid="B104-ijms-21-09049" ref-type="bibr">104</xref>,<xref rid="B105-ijms-21-09049" ref-type="bibr">105</xref>]. Other studies suggest that metabolic pathways and noncannabinoid receptors are involved with immunomodulatory effect of cannabinoids [<xref rid="B106-ijms-21-09049" ref-type="bibr">106</xref>,<xref rid="B107-ijms-21-09049" ref-type="bibr">107</xref>,<xref rid="B108-ijms-21-09049" ref-type="bibr">108</xref>]. Importantly, agonists of cannabinoid receptor have a psychotropic effect [<xref rid="B107-ijms-21-09049" ref-type="bibr">107</xref>]. Therefore, there is an effort to identify the compounds which have therapeutic effects but that are not able to activate CB1 and CB2 to avoid the psychotropic effect. THCA showed their immunomodulatory effect through a different metabolic pathway, without activating CB1 and CB2 [<xref rid="B56-ijms-21-09049" ref-type="bibr">56</xref>]. THCA targeted phosphatidyl choline specific phospholipase C (PC-PLC) enzymatic activity in phospholipids metabolism and inhibits proinflammatory cytokine tumor necrosis factor alpha (TNF-&#x003b1;) release from lipopolysaccharide (LPS)-activated U937 macrophages and peripheral blood macrophages in a dose-dependent manner with the EC<sub>50</sub> value of approximately 50 &#x000b5;M.</p></sec><sec id="sec2dot4dot2-ijms-21-09049"><title>2.4.2. Anti-Inflammatory Role</title><p>Cyclooxygenase 1 (COX1) and cyclooxygenase 2 (COX2) are essential to produce prostaglandins which are important for the inflammatory reaction. THCA inhibited COX1 (IC<sub>50</sub> of 1700 &#x000b5;M) and COX2 (IC<sub>50</sub> of 630 &#x000b5;M) using an enzyme-based in vitro assay and human colon adenocarcinoma HT29 cell line. Prostaglandin production was also inhibited (10% inhibition, 62.5 &#x000b5;M) in HT29 cell line by THCA [<xref rid="B57-ijms-21-09049" ref-type="bibr">57</xref>]. Another report showed that THCA inhibited COX2 expression in a dose-dependent manner in three colon cancer cell lines HCT116, HT29, and CaCO2. In addition, THCA inhibited Matrix metallopeptidase 9 (MMP-9) expression in colon cell lines indicating that THCA plays an efficient role against colon inflammation [<xref rid="B58-ijms-21-09049" ref-type="bibr">58</xref>].</p><p>CBDA exerted anti-inflammatory activity in receptor level by stimulating vanilloid 1 and ankyrin 1 transient receptor potential (TRP) channels (TRPV1 and TRPA1, respectively) or by antagonizing the Transient Receptor Potential Cation Channel Subfamily M Member 8 (TRPM8) with IC<sub>50</sub> value ranging 0.9&#x02013;1.6 &#x000b5;M [<xref rid="B67-ijms-21-09049" ref-type="bibr">67</xref>]. COX2 is mainly involved in an inflammatory response. CBDA acts as a selective inhibitor of COX2 with an IC<sub>50</sub> value of approximately 2 &#x000b5;M [<xref rid="B68-ijms-21-09049" ref-type="bibr">68</xref>]. Intraperitoneal administration of rodent with CBDA (10 &#x003bc;g/kg) 60 min prior to treatment with carrageenan produced anti-inflammatory effects in a dose-dependent manner but orally did not [<xref rid="B69-ijms-21-09049" ref-type="bibr">69</xref>].</p></sec><sec id="sec2dot4dot3-ijms-21-09049"><title>2.4.3. Neuroprotective Role</title><p>Noncompetitive inhibitors of the NADH ubiquinone reductase (complex 1), such as 1-methyl-4-phenyl pyridinium (MPP<sup>+</sup>), are used as a model compound in dopaminergic neuronal degeneration to study Parkinson&#x02019;s disease (PD). THCA reduced the degenerative effect of MPP<sup>+</sup> in dopaminergic neurons and increased cell survival at the highest tested dose of 10 &#x000b5;M in mice mesencephalic cultures [<xref rid="B59-ijms-21-09049" ref-type="bibr">59</xref>]. Another model compound 3-nitropropionic acid (3-NPA) is used in the research of huntingtin disease (HD) which acts as a complex II inhibitor of the mitochondrial respiratory chain, resulting in progressive loss of locomotor and striatal degeneration. THCA mitigated degenerative effects of 3-NPA, through a PPAR&#x003b3;-dependent pathway in N2a cell [<xref rid="B60-ijms-21-09049" ref-type="bibr">60</xref>].</p><p>Phytocannabinoids canabigerol (CBG) and cannabidivarin (CBDV) are the most promising candidates as neuroprotectants, while &#x00394;9-tetrahydrocannabivarin (&#x00394;9-THCV), &#x00394;9-THCA, cannabichromene (CBC), and cannabinol (CBN) have limited but encouraging data as neuroprotectants. However, little is known with neuroprotective potential of CBDA [<xref rid="B109-ijms-21-09049" ref-type="bibr">109</xref>].</p></sec><sec id="sec2dot4dot4-ijms-21-09049"><title>2.4.4. Anticancer Activity</title><p>THCA inhibited cell proliferation in various prostate carcinoma cell (PCC) lines, including (i) androgen-receptor positive cells (LNCaP and 22RV1) with IC<sub>50</sub> of 22.1 &#x000b1; 2 &#x000b5;M or 17.1 &#x000b1; 1 &#x000b5;M in the presence or absence of serum, respectively, (ii) androgen-receptor negative cells (DU-145 and PC-3) with IC<sub>50</sub> of &#x0003e;25 &#x000b5;M (21.9% inhibition) or 21.6 &#x000b1; 2 &#x000b5;M in the presence or absence of serum, respectively [<xref rid="B62-ijms-21-09049" ref-type="bibr">62</xref>]. Cell proliferation of two different human breast carcinoma (HBC) cells, triple-negative MDA-MB-231 and HER2-negative MCF-7, were inhibited with IC<sub>50</sub> value of 18.2 &#x000b1; 5 &#x000b5;M and 9.8 &#x000b1; 0.4 &#x000b5;M, respectively [<xref rid="B61-ijms-21-09049" ref-type="bibr">61</xref>].</p><p>CBDA reduced COX2 expression in triple-negative MDA-MB-231 human breast cancer cell with a concentration of 5 &#x000b5;M by abrogating the transcriptional activities of both activator protein-I (AP-I) and peroxisome proliferator-activated receptor PPAR&#x003b2;/&#x003b4; [<xref rid="B63-ijms-21-09049" ref-type="bibr">63</xref>]. CBDA inhibited human breast cancer cell metastasis by suppressing COX2 and proto-oncogene c-Fos expression and upregulating the expression of SHARP1(1.72-fold), a suppressor of breast cancer metastasis [<xref rid="B63-ijms-21-09049" ref-type="bibr">63</xref>,<xref rid="B64-ijms-21-09049" ref-type="bibr">64</xref>,<xref rid="B65-ijms-21-09049" ref-type="bibr">65</xref>,<xref rid="B66-ijms-21-09049" ref-type="bibr">66</xref>].</p></sec><sec id="sec2dot4dot5-ijms-21-09049"><title>2.4.5. Antiemetic Effect and Anticonvulsant Effect</title><p>5-HT1A receptors control the antinausea effects of CBDA. In vivo mice study showed that CBDA inhibited vomiting caused by toxins and induced 5-HT1A receptor activity [<xref rid="B70-ijms-21-09049" ref-type="bibr">70</xref>,<xref rid="B71-ijms-21-09049" ref-type="bibr">71</xref>]. The pharmacokinetics of phytocannabinoid acids (including CBDA with others) showed that plasma level absorption occurred rapidly, and the brain/plasma ratio was very low. However, when CBDA was administered in an alternate Tween 80-based vehicle, the value of the brain/plasma ratio was 1.9 and in <italic>Scn1a</italic><sup>RX/+</sup> mouse model of Dravet syndrome, and CBDA showed potent anticonvulsant activity [<xref rid="B72-ijms-21-09049" ref-type="bibr">72</xref>].</p></sec></sec></sec><sec sec-type="conclusions" id="sec3-ijms-21-09049"><title>3. Conclusions</title><p>Plant derived natural compounds are used throughout the world for medicinal purposes. Plant derived salicylates target many human proteins and can play prominent roles in human disease treatment. Initially, researchers focused on acetyl salicylate (aspirin) and showed that it can be a good target for drug development for many human diseases. Recent findings suggest that many natural salicylates have pharmacological roles. Our focused salicylates amorfrutins, ginkgolic acid, grifolic acid, THCA, and CBDA target different human proteins and pathways. It appears clear that these natural salicylates may be promising natural compounds in treating different human diseases. Some medicinal plants and natural products showed relevant results in clinical trials [<xref rid="B110-ijms-21-09049" ref-type="bibr">110</xref>,<xref rid="B111-ijms-21-09049" ref-type="bibr">111</xref>,<xref rid="B112-ijms-21-09049" ref-type="bibr">112</xref>]. However, there are very limited clinical trials available with these salicylates. Our review suggests that further clinical trials with different salicylates on different human diseases will be needed based on many preclinical results with amorfrutins (antidiabetic, anticancer, and anti-inflammatory activities), ginkgolic acid (anticancer, neuroprotective, and antiviral activities), grifolic acid (antitumor activity), THCA (immunomodulatory, anti-inflammatory, neuroprotective, and antineoplastic activities), and CBDA (anticancer, anti-inflammatory, antiemetic, and anticonvulsant activities).</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Funding</title><p>This work was supported by grants from Basic Research Program through the National Research Foundation of Korea (NRF) grant funded by Korea government (MSIT) (2019R1F1A1060416) and from the Nature Bioindustry Technology Development and Enterprise Support Project (BTD &#x00026; ESP) in Gyeongsangbuk-do. The APC was funded by (BTD &#x00026; ESP) in Gyeongsangbuk-do.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-21-09049"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlot</surname><given-names>A.C.</given-names></name><name><surname>Dempsey</surname><given-names>D.A.</given-names></name><name><surname>Klessig</surname><given-names>D.F.</given-names></name></person-group><article-title>Salicylic acid, a multifaceted hormone to combat disease</article-title><source>Annu. Rev. Phytopathol.</source><year>2009</year><volume>47</volume><fpage>177</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1146/annurev.phyto.050908.135202</pub-id><?supplied-pmid 19400653?><pub-id pub-id-type="pmid">19400653</pub-id></element-citation></ref><ref id="B2-ijms-21-09049"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedner</surname><given-names>T.</given-names></name><name><surname>Everts</surname><given-names>B.</given-names></name></person-group><article-title>The early clinical history of salicylates in rheumatology and pain</article-title><source>Clin. Rheumatol.</source><year>1998</year><volume>17</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1007/BF01450953</pub-id><?supplied-pmid 9586674?><pub-id pub-id-type="pmid">9586674</pub-id></element-citation></ref><ref id="B3-ijms-21-09049"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fecka</surname><given-names>I.</given-names></name></person-group><article-title>Qualitative and quantitative determination of hydrolysable tannins and other polyphenols in herbal products from meadowsweet and dog rose</article-title><source>Phytochem. Anal.</source><year>2009</year><volume>20</volume><fpage>177</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1002/pca.1113</pub-id><pub-id pub-id-type="pmid">19291675</pub-id></element-citation></ref><ref id="B4-ijms-21-09049"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pino</surname><given-names>J.A.</given-names></name><name><surname>Mesa</surname><given-names>J.</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>Y.</given-names></name><name><surname>Mart&#x000ed;</surname><given-names>M.P.</given-names></name><name><surname>Marbot</surname><given-names>R.</given-names></name></person-group><article-title>Volatile Components from Mango (<italic>Mangifera indica</italic> L.) Cultivars</article-title><source>J. Agric. Food Chem.</source><year>2005</year><volume>53</volume><fpage>2213</fpage><lpage>2223</lpage><pub-id pub-id-type="doi">10.1021/jf0402633</pub-id><?supplied-pmid 15769159?><pub-id pub-id-type="pmid">15769159</pub-id></element-citation></ref><ref id="B5-ijms-21-09049"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Towers</surname><given-names>G.</given-names></name><name><surname>Tse</surname><given-names>A.</given-names></name><name><surname>Maass</surname><given-names>W.</given-names></name></person-group><article-title>Phenolic acids and phenolic glycosides of Gaultheria species</article-title><source>Phytochem.</source><year>1966</year><volume>5</volume><fpage>677</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1016/S0031-9422(00)83646-8</pub-id></element-citation></ref><ref id="B6-ijms-21-09049"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>N.</given-names></name><name><surname>Yayli</surname><given-names>N.</given-names></name><name><surname>Misir</surname><given-names>G.</given-names></name><name><surname>Karaoglu</surname><given-names>S.</given-names></name></person-group><article-title>Chemical composition and antimicrobial activities of the essential oils of Viburnum opulus, Viburnum lantana and Viburnum oriental</article-title><source>Asian J. Chem.</source><year>2008</year><volume>20</volume><fpage>3324</fpage><lpage>3330</lpage></element-citation></ref><ref id="B7-ijms-21-09049"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klessig</surname><given-names>D.F.</given-names></name><name><surname>Tian</surname><given-names>M.</given-names></name><name><surname>Choi</surname><given-names>H.W.</given-names></name></person-group><article-title>Multiple Targets of Salicylic Acid and Its Derivatives in Plants and Animals</article-title><source>Front. Immunol.</source><year>2016</year><volume>7</volume><fpage>206</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2016.00206</pub-id><pub-id pub-id-type="pmid">27303403</pub-id></element-citation></ref><ref id="B8-ijms-21-09049"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anthony</surname><given-names>J.C.</given-names></name><name><surname>Breitner</surname><given-names>J.C.S.</given-names></name><name><surname>Zandi</surname><given-names>P.P.</given-names></name><name><surname>Meyer</surname><given-names>M.R.</given-names></name><name><surname>Jurasova</surname><given-names>I.</given-names></name><name><surname>Norton</surname><given-names>M.C.</given-names></name><name><surname>Stone</surname><given-names>S.V.</given-names></name></person-group><article-title>Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: The Cache County Study</article-title><source>Neurology</source><year>2000</year><volume>54</volume><fpage>2066</fpage><lpage>2071</lpage><pub-id pub-id-type="doi">10.1212/WNL.54.11.2066</pub-id><pub-id pub-id-type="pmid">10851364</pub-id></element-citation></ref><ref id="B9-ijms-21-09049"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thun</surname><given-names>M.J.</given-names></name><name><surname>Jacobs</surname><given-names>E.J.</given-names></name><name><surname>Patrono</surname><given-names>C.</given-names></name></person-group><article-title>The role of aspirin in cancer prevention</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2012</year><volume>9</volume><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2011.199</pub-id><pub-id pub-id-type="pmid">22473097</pub-id></element-citation></ref><ref id="B10-ijms-21-09049"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirakawa</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Man</surname><given-names>N.</given-names></name><name><surname>Maksimoska</surname><given-names>J.</given-names></name><name><surname>Sorum</surname><given-names>A.W.</given-names></name><name><surname>Lim</surname><given-names>H.W.</given-names></name><name><surname>Lee</surname><given-names>I.S.</given-names></name><name><surname>Shimazu</surname><given-names>T.</given-names></name><name><surname>Newman</surname><given-names>J.C.</given-names></name><name><surname>Schr&#x000f6;der</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity</article-title><source>eLife</source><year>2016</year><volume>5</volume><fpage>e11156</fpage><pub-id pub-id-type="doi">10.7554/eLife.11156</pub-id><pub-id pub-id-type="pmid">27244239</pub-id></element-citation></ref><ref id="B11-ijms-21-09049"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopp</surname><given-names>E.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name></person-group><article-title>Inhibition of NF-&#x003ba;B by Sodium Salicylate and Aspirin</article-title><source>Science</source><year>1994</year><volume>265</volume><fpage>956</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1126/science.8052854</pub-id><?supplied-pmid 8052854?><pub-id pub-id-type="pmid">8052854</pub-id></element-citation></ref><ref id="B12-ijms-21-09049"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrowska</surname><given-names>H.</given-names></name></person-group><article-title>Inhibition of human platelet cathepsin A by non-steroidal anti-inflammatory drugs&#x02014;in vitro study</article-title><source>Pol. J. Pharmacol.</source><year>1996</year><volume>48</volume><fpage>113</fpage><lpage>116</lpage><?supplied-pmid 9112639?><pub-id pub-id-type="pmid">9112639</pub-id></element-citation></ref><ref id="B13-ijms-21-09049"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevenson</surname><given-names>M.A.</given-names></name><name><surname>Zhao</surname><given-names>M.J.</given-names></name><name><surname>Asea</surname><given-names>A.</given-names></name><name><surname>Coleman</surname><given-names>C.N.</given-names></name><name><surname>Calderwood</surname><given-names>S.K.</given-names></name></person-group><article-title>Salicylic Acid and Aspirin Inhibit the Activity of RSK2 Kinase and Repress RSK2-Dependent Transcription of Cyclic AMP Response Element Binding Protein- and NF-&#x003ba;B-Responsive Genes</article-title><source>J. Immunol.</source><year>1999</year><volume>163</volume><fpage>5608</fpage><?supplied-pmid 10553090?><pub-id pub-id-type="pmid">10553090</pub-id></element-citation></ref><ref id="B14-ijms-21-09049"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dachineni</surname><given-names>R.</given-names></name><name><surname>Ai</surname><given-names>G.</given-names></name><name><surname>Kumar</surname><given-names>D.R.</given-names></name><name><surname>Sadhu</surname><given-names>S.S.</given-names></name><name><surname>Tummala</surname><given-names>H.</given-names></name><name><surname>Bhat</surname><given-names>G.J.</given-names></name></person-group><article-title>Cyclin A2 and CDK2 as Novel Targets of Aspirin and Salicylic Acid: A Potential Role in Cancer Prevention</article-title><source>Mol. Cancer Res.</source><year>2016</year><volume>14</volume><fpage>241</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-15-0360</pub-id><?supplied-pmid 26685215?><pub-id pub-id-type="pmid">26685215</pub-id></element-citation></ref><ref id="B15-ijms-21-09049"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>O.H.</given-names></name><name><surname>Bukhave</surname><given-names>K.</given-names></name><name><surname>Elmgreen</surname><given-names>J.</given-names></name><name><surname>Ahnfelt-R&#x000f8;nne</surname><given-names>I.</given-names></name></person-group><article-title>Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid</article-title><source>Dig. Dis. Sci.</source><year>1987</year><volume>32</volume><fpage>577</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1007/BF01296156</pub-id><?supplied-pmid 2882965?><pub-id pub-id-type="pmid">2882965</pub-id></element-citation></ref><ref id="B16-ijms-21-09049"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>H.W.</given-names></name><name><surname>Tian</surname><given-names>M.</given-names></name><name><surname>Manohar</surname><given-names>M.</given-names></name><name><surname>Harraz</surname><given-names>M.M.</given-names></name><name><surname>Park</surname><given-names>S.W.</given-names></name><name><surname>Schroeder</surname><given-names>F.C.</given-names></name><name><surname>Snyder</surname><given-names>S.H.</given-names></name><name><surname>Klessig</surname><given-names>D.F.</given-names></name></person-group><article-title>Human GAPDH Is a Target of Aspirin&#x02019;s Primary Metabolite Salicylic Acid and Its Derivatives</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0143447</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0143447</pub-id><?supplied-pmid 26606248?><pub-id pub-id-type="pmid">26606248</pub-id></element-citation></ref><ref id="B17-ijms-21-09049"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanahan</surname><given-names>F.</given-names></name><name><surname>Niederlehner</surname><given-names>A.</given-names></name><name><surname>Carramanzana</surname><given-names>N.</given-names></name><name><surname>Anton</surname><given-names>P.</given-names></name></person-group><article-title>Sulfasalazine inhibits the binding of TNF&#x003b1; to its receptor</article-title><source>Immunopharmacology</source><year>1990</year><volume>20</volume><fpage>217</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/0162-3109(90)90037-F</pub-id><pub-id pub-id-type="pmid">1981213</pub-id></element-citation></ref><ref id="B18-ijms-21-09049"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>J.A.</given-names></name><name><surname>Saunders</surname><given-names>M.</given-names></name><name><surname>Barnes</surname><given-names>P.J.</given-names></name><name><surname>Newton</surname><given-names>R.</given-names></name><name><surname>Belvisi</surname><given-names>M.G.</given-names></name></person-group><article-title>Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: Role of arachidonic acid</article-title><source>Mol. Pharmacol.</source><year>1997</year><volume>51</volume><fpage>907</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1124/mol.51.6.907</pub-id><pub-id pub-id-type="pmid">9187256</pub-id></element-citation></ref><ref id="B19-ijms-21-09049"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>H.W.</given-names></name><name><surname>Tian</surname><given-names>M.</given-names></name><name><surname>Song</surname><given-names>F.</given-names></name><name><surname>Venereau</surname><given-names>E.</given-names></name><name><surname>Preti</surname><given-names>A.</given-names></name><name><surname>Park</surname><given-names>S.W.</given-names></name><name><surname>Hamilton</surname><given-names>K.</given-names></name><name><surname>Swapna</surname><given-names>G.V.T.</given-names></name><name><surname>Manohar</surname><given-names>M.</given-names></name><name><surname>Moreau</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Aspirin&#x02019;s Active Metabolite Salicylic Acid Targets High Mobility Group Box 1 to Modulate Inflammatory Responses</article-title><source>Mol. Med.</source><year>2015</year><volume>21</volume><fpage>526</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.2119/molmed.2015.00148</pub-id><pub-id pub-id-type="pmid">26101955</pub-id></element-citation></ref><ref id="B20-ijms-21-09049"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>H.W.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Powell</surname><given-names>A.F.</given-names></name><name><surname>Strickler</surname><given-names>S.R.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Dempsey</surname><given-names>D.A.</given-names></name><name><surname>Schroeder</surname><given-names>F.C.</given-names></name><name><surname>Klessig</surname><given-names>D.F.</given-names></name></person-group><article-title>A genome-wide screen for human salicylic acid (SA)-binding proteins reveals targets through which SA may influence development of various diseases</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s41598-019-49234-6</pub-id><pub-id pub-id-type="pmid">30626917</pub-id></element-citation></ref><ref id="B21-ijms-21-09049"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vane</surname><given-names>J.R.</given-names></name></person-group><article-title>Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs</article-title><source>Nat. New Biol.</source><year>1971</year><volume>231</volume><fpage>232</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1038/newbio231232a0</pub-id><?supplied-pmid 5284360?><pub-id pub-id-type="pmid">5284360</pub-id></element-citation></ref><ref id="B22-ijms-21-09049"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>J.A.</given-names></name><name><surname>Akarasereenont</surname><given-names>P.</given-names></name><name><surname>Thiemermann</surname><given-names>C.</given-names></name><name><surname>Flower</surname><given-names>R.J.</given-names></name><name><surname>Vane</surname><given-names>J.R.</given-names></name></person-group><article-title>Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1993</year><volume>90</volume><fpage>11693</fpage><lpage>11697</lpage><pub-id pub-id-type="doi">10.1073/pnas.90.24.11693</pub-id><?supplied-pmid 8265610?><pub-id pub-id-type="pmid">8265610</pub-id></element-citation></ref><ref id="B23-ijms-21-09049"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>M.J.</given-names></name><name><surname>Yamamoto</surname><given-names>Y.</given-names></name><name><surname>Gaynor</surname><given-names>R.B.</given-names></name></person-group><article-title>The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta</article-title><source>Nature</source><year>1998</year><volume>396</volume><fpage>77</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/23948</pub-id><?supplied-pmid 9817203?><pub-id pub-id-type="pmid">9817203</pub-id></element-citation></ref><ref id="B24-ijms-21-09049"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>S.W.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Tracy</surname><given-names>T.E.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Shirakawa</surname><given-names>K.</given-names></name><name><surname>Minami</surname><given-names>S.S.</given-names></name><name><surname>Defensor</surname><given-names>E.</given-names></name><name><surname>Mok</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits</article-title><source>Nat. Med.</source><year>2015</year><volume>21</volume><fpage>1154</fpage><lpage>1162</lpage><pub-id pub-id-type="doi">10.1038/nm.3951</pub-id><pub-id pub-id-type="pmid">26390242</pub-id></element-citation></ref><ref id="B25-ijms-21-09049"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitscher</surname><given-names>L.A.</given-names></name><name><surname>Park</surname><given-names>Y.H.</given-names></name><name><surname>AlShamma</surname><given-names>A.</given-names></name><name><surname>Hudson</surname><given-names>P.</given-names></name><name><surname>Haas</surname><given-names>T.</given-names></name></person-group><article-title>Amorfrutin A and B, bibenzyl antimicrobial agents from Amorpha fruticosa</article-title><source>Phytochemistry</source><year>1981</year><volume>20</volume><fpage>781</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1016/0031-9422(81)85174-6</pub-id></element-citation></ref><ref id="B26-ijms-21-09049"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isah</surname><given-names>T.</given-names></name></person-group><article-title>Rethinking Ginkgo biloba L.: Medicinal uses and conservation</article-title><source>Pharmacogn. Rev.</source><year>2015</year><volume>9</volume><fpage>140</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.4103/0973-7847.162137</pub-id><pub-id pub-id-type="pmid">26392712</pub-id></element-citation></ref><ref id="B27-ijms-21-09049"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>T.</given-names></name><name><surname>Kuwahara</surname><given-names>S.</given-names></name><name><surname>Ogura</surname><given-names>Y.</given-names></name></person-group><article-title>Synthesis of amorfrutins B and D from amorfrutin A ethyl ester</article-title><source>Tetrahedron Lett.</source><year>2020</year><volume>61</volume><fpage>151477</fpage><pub-id pub-id-type="doi">10.1016/j.tetlet.2019.151477</pub-id></element-citation></ref><ref id="B28-ijms-21-09049"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidner</surname><given-names>C.</given-names></name><name><surname>Rousseau</surname><given-names>M.</given-names></name><name><surname>Micikas</surname><given-names>R.J.</given-names></name><name><surname>Fischer</surname><given-names>C.</given-names></name><name><surname>Plauth</surname><given-names>A.</given-names></name><name><surname>Wowro</surname><given-names>S.J.</given-names></name><name><surname>Siems</surname><given-names>K.</given-names></name><name><surname>Hetterling</surname><given-names>G.</given-names></name><name><surname>Kliem</surname><given-names>M.</given-names></name><name><surname>Schroeder</surname><given-names>F.C.</given-names></name><etal/></person-group><article-title>Amorfrutin C Induces Apoptosis and Inhibits Proliferation in Colon Cancer Cells through Targeting Mitochondria</article-title><source>J. Nat. Prod.</source><year>2016</year><volume>79</volume><fpage>2</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.5b00072</pub-id><pub-id pub-id-type="pmid">26731300</pub-id></element-citation></ref><ref id="B29-ijms-21-09049"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>X.G.</given-names></name><name><surname>Bernart</surname><given-names>M.W.</given-names></name><name><surname>Nolan</surname><given-names>G.S.</given-names></name><name><surname>Lin</surname><given-names>L.Z.</given-names></name><name><surname>Lindenmaier</surname><given-names>M.P.</given-names></name></person-group><article-title>High-Performance Liquid Chromatography--Electrospray Ionization-Mass Spectrometry Study of Ginkgolic Acid in the leaves and Fruits of the Ginkgo Tree (Ginkgo biloba)</article-title><source>J. Chromatogr. Sci.</source><year>2000</year><volume>38</volume><fpage>169</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1093/chromsci/38.4.169</pub-id><pub-id pub-id-type="pmid">10766484</pub-id></element-citation></ref><ref id="B30-ijms-21-09049"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.F.</given-names></name><name><surname>Jiang</surname><given-names>F.</given-names></name><name><surname>Liang</surname><given-names>X.Y.</given-names></name><name><surname>Wei</surname><given-names>L.-L.</given-names></name><name><surname>Zhao</surname><given-names>Y.Y.</given-names></name><name><surname>Ma</surname><given-names>Q.</given-names></name><name><surname>Hu</surname><given-names>Y.S.</given-names></name><name><surname>Su</surname><given-names>X.</given-names></name></person-group><article-title>Grifolic acid causes osteosarcoma cell death in vitro and in tumor-bearing mice</article-title><source>Biomed. Pharmacother.</source><year>2018</year><volume>103</volume><fpage>1035</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.04.132</pub-id><pub-id pub-id-type="pmid">29710661</pub-id></element-citation></ref><ref id="B31-ijms-21-09049"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>J.K.</given-names></name><name><surname>Lu</surname><given-names>Z.X.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>S.F.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Tan</surname><given-names>M.</given-names></name><name><surname>Weng</surname><given-names>X.X.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name></person-group><article-title>Grifolin, a potential antitumor natural product from the mushroomAlbatrellus confluens, inhibits tumor cell growth by inducing apoptosis in vitro</article-title><source>FEBS Lett.</source><year>2005</year><volume>579</volume><fpage>3437</fpage><lpage>3443</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2005.05.013</pub-id><?supplied-pmid 15949805?><pub-id pub-id-type="pmid">15949805</pub-id></element-citation></ref><ref id="B32-ijms-21-09049"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>S.</given-names></name><name><surname>Pang</surname><given-names>R.P.</given-names></name><name><surname>Shen</surname><given-names>J.N.</given-names></name><name><surname>Huang</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>J.G.</given-names></name></person-group><article-title>Grifolin induces apoptosis via inhibition of PI3K/AKT signalling pathway in human osteosarcoma cells</article-title><source>Apoptosis</source><year>2007</year><volume>12</volume><fpage>1317</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1007/s10495-007-0062-z</pub-id><?supplied-pmid 17333316?><pub-id pub-id-type="pmid">17333316</pub-id></element-citation></ref><ref id="B33-ijms-21-09049"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Xiao</surname><given-names>L.</given-names></name><name><surname>Xia</surname><given-names>X.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Zhong</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Hongde</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Grifolin directly targets ERK1/2 to epigenetically suppress cancer cell metastasis</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>42704</fpage><lpage>42716</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.5678</pub-id><?supplied-pmid 26516701?><pub-id pub-id-type="pmid">26516701</pub-id></element-citation></ref><ref id="B34-ijms-21-09049"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Che</surname><given-names>X.</given-names></name><name><surname>Yan</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Dongol</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Lv</surname><given-names>Q.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name></person-group><article-title>Grifolin induces autophagic cell death by inhibiting the Akt/mTOR/S6K pathway in human ovarian cancer cells</article-title><source>Oncol. Rep.</source><year>2016</year><volume>36</volume><fpage>1041</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.3892/or.2016.4840</pub-id><pub-id pub-id-type="pmid">27277722</pub-id></element-citation></ref><ref id="B35-ijms-21-09049"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Grifolin exhibits anti-cancer activity by inhibiting the development and invasion of gastric tumor cells</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>21454</fpage><lpage>21460</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.15250</pub-id><pub-id pub-id-type="pmid">28206955</pub-id></element-citation></ref><ref id="B36-ijms-21-09049"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.F.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yan</surname><given-names>A.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Xie</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Grifolic acid induces GH3 adenoma cell death by inhibiting ATP production through a GPR120-independent mechanism</article-title><source>BMC Pharmacol. Toxicol.</source><year>2018</year><volume>19</volume><elocation-id>26</elocation-id><pub-id pub-id-type="doi">10.1186/s40360-018-0215-4</pub-id><pub-id pub-id-type="pmid">29843779</pub-id></element-citation></ref><ref id="B37-ijms-21-09049"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andre</surname><given-names>C.M.</given-names></name><name><surname>Hausman</surname><given-names>J.F.</given-names></name><name><surname>Guerriero</surname><given-names>G.</given-names></name></person-group><article-title>Cannabis sativa: The Plant of the Thousand and One Molecules</article-title><source>Front. Plant Sci.</source><year>2016</year><volume>7</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.3389/fpls.2016.00019</pub-id><pub-id pub-id-type="pmid">26870049</pub-id></element-citation></ref><ref id="B38-ijms-21-09049"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brighenti</surname><given-names>V.</given-names></name><name><surname>Pellati</surname><given-names>F.</given-names></name><name><surname>Steinbach</surname><given-names>M.</given-names></name><name><surname>Maran</surname><given-names>D.</given-names></name><name><surname>Benvenuti</surname><given-names>S.</given-names></name></person-group><article-title>Development of a new extraction technique and HPLC method for the analysis of non-psychoactive cannabinoids in fibre-type <italic>Cannabis sativa</italic> L. (hemp)</article-title><source>J. Pharm. Biomed. Anal.</source><year>2017</year><volume>143</volume><fpage>228</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2017.05.049</pub-id><pub-id pub-id-type="pmid">28609672</pub-id></element-citation></ref><ref id="B39-ijms-21-09049"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellati</surname><given-names>F.</given-names></name><name><surname>Brighenti</surname><given-names>V.</given-names></name><name><surname>Sperlea</surname><given-names>J.</given-names></name><name><surname>Marchetti</surname><given-names>L.</given-names></name><name><surname>Bertelli</surname><given-names>D.</given-names></name><name><surname>Benvenuti</surname><given-names>S.</given-names></name></person-group><article-title>New Methods for the Comprehensive Analysis of Bioactive Compounds in <italic>Cannabis sativa</italic> L. (hemp)</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>2639</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23102639</pub-id></element-citation></ref><ref id="B40-ijms-21-09049"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidner</surname><given-names>C.</given-names></name><name><surname>De Groot</surname><given-names>J.C.</given-names></name><name><surname>Prasad</surname><given-names>A.</given-names></name><name><surname>Freiwald</surname><given-names>A.</given-names></name><name><surname>Quedenau</surname><given-names>C.</given-names></name><name><surname>Kliem</surname><given-names>M.</given-names></name><name><surname>Witzke</surname><given-names>A.</given-names></name><name><surname>Kodelja</surname><given-names>V.</given-names></name><name><surname>Han</surname><given-names>C.</given-names></name><name><surname>Giegold</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Amorfrutins are potent antidiabetic dietary natural products</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>7257</fpage><lpage>7262</lpage><pub-id pub-id-type="doi">10.1073/pnas.1116971109</pub-id><pub-id pub-id-type="pmid">22509006</pub-id></element-citation></ref><ref id="B41-ijms-21-09049"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidner</surname><given-names>C.</given-names></name><name><surname>Wowro</surname><given-names>S.J.</given-names></name><name><surname>Freiwald</surname><given-names>A.</given-names></name><name><surname>Kawamoto</surname><given-names>K.</given-names></name><name><surname>Witzke</surname><given-names>A.</given-names></name><name><surname>Kliem</surname><given-names>M.</given-names></name><name><surname>Siems</surname><given-names>K.</given-names></name><name><surname>M&#x000fc;ller-Kuhrt</surname><given-names>L.</given-names></name><name><surname>Schroeder</surname><given-names>F.C.</given-names></name><name><surname>Sauer</surname><given-names>S.</given-names></name></person-group><article-title>Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPAR&#x003b3;) agonist with potent glucose-lowering properties</article-title><source>Diabetology</source><year>2013</year><volume>56</volume><fpage>1802</fpage><lpage>1812</lpage><pub-id pub-id-type="doi">10.1007/s00125-013-2920-2</pub-id><?supplied-pmid 23680913?><pub-id pub-id-type="pmid">23680913</pub-id></element-citation></ref><ref id="B42-ijms-21-09049"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuhr</surname><given-names>L.</given-names></name><name><surname>Rousseau</surname><given-names>M.</given-names></name><name><surname>Plauth</surname><given-names>A.</given-names></name><name><surname>Schroeder</surname><given-names>F.C.</given-names></name><name><surname>Sauer</surname><given-names>S.</given-names></name></person-group><article-title>Amorfrutins Are Natural PPAR&#x003b3; Agonists with Potent Anti-inflammatory Properties</article-title><source>J. Nat. Prod.</source><year>2015</year><volume>78</volume><fpage>1160</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1021/np500747y</pub-id><?supplied-pmid 25938459?><pub-id pub-id-type="pmid">25938459</pub-id></element-citation></ref><ref id="B43-ijms-21-09049"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meierhofer</surname><given-names>D.</given-names></name><name><surname>Weidner</surname><given-names>C.</given-names></name><name><surname>Hartmann</surname><given-names>L.</given-names></name><name><surname>Mayr</surname><given-names>J.A.</given-names></name><name><surname>Han</surname><given-names>C.T.</given-names></name><name><surname>Schroeder</surname><given-names>F.C.</given-names></name><name><surname>Sauer</surname><given-names>S.</given-names></name></person-group><article-title>Protein Sets Define Disease States and PredictIn VivoEffects of Drug Treatment</article-title><source>Mol. Cell. Proteom.</source><year>2013</year><volume>12</volume><fpage>1965</fpage><lpage>1979</lpage><pub-id pub-id-type="doi">10.1074/mcp.M112.025031</pub-id><?supplied-pmid 23579186?><pub-id pub-id-type="pmid">23579186</pub-id></element-citation></ref><ref id="B44-ijms-21-09049"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>C.</given-names></name><name><surname>Na</surname><given-names>N.</given-names></name><name><surname>Sheng</surname><given-names>H.</given-names></name><name><surname>Feng</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Deng</surname><given-names>Z.</given-names></name></person-group><article-title>Ginkgolic acid inhibits the growth of renal cell carcinoma cells via inactivation of the EGFR signaling pathway</article-title><source>Exp. Ther. Med.</source><year>2020</year><volume>19</volume><fpage>2949</fpage><lpage>2956</lpage><pub-id pub-id-type="doi">10.3892/etm.2020.8570</pub-id><pub-id pub-id-type="pmid">32256780</pub-id></element-citation></ref><ref id="B45-ijms-21-09049"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamdoun</surname><given-names>S.</given-names></name><name><surname>Efferth</surname><given-names>T.</given-names></name></person-group><article-title>Ginkgolic acids inhibit migration in breast cancer cells by inhibition of NEMO sumoylation and NF-&#x003ba;B activity</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>35103</fpage><lpage>35115</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16626</pub-id><pub-id pub-id-type="pmid">28402272</pub-id></element-citation></ref><ref id="B46-ijms-21-09049"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baek</surname><given-names>S.H.</given-names></name><name><surname>Ko</surname><given-names>J.H.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Nam</surname><given-names>D.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>S.G.</given-names></name><name><surname>Yang</surname><given-names>W.M.</given-names></name><name><surname>Um</surname><given-names>J.Y.</given-names></name><etal/></person-group><article-title>Ginkgolic Acid Inhibits Invasion and Migration and TGF-&#x003b2;-Induced EMT of Lung Cancer Cells through PI3K/Akt/mTOR Inactivation</article-title><source>J. Cell. Physiol.</source><year>2016</year><volume>232</volume><fpage>346</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1002/jcp.25426</pub-id><pub-id pub-id-type="pmid">27177359</pub-id></element-citation></ref><ref id="B47-ijms-21-09049"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Duan</surname><given-names>W.</given-names></name><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Lei</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>Z.</given-names></name><name><surname>Nan</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>20993</fpage><lpage>21003</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3663</pub-id><pub-id pub-id-type="pmid">25895130</pub-id></element-citation></ref><ref id="B48-ijms-21-09049"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>L.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Wei</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Ginkgolic acid inhibits the invasiveness of colon cancer cells through AMPK activation</article-title><source>Oncol. Lett.</source><year>2017</year><volume>14</volume><fpage>5831</fpage><lpage>5838</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.6967</pub-id><pub-id pub-id-type="pmid">29113214</pub-id></element-citation></ref><ref id="B49-ijms-21-09049"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baek</surname><given-names>S.H.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>C.</given-names></name><name><surname>Ko</surname><given-names>J.H.</given-names></name><name><surname>Ryu</surname><given-names>S.H.</given-names></name><name><surname>Lee</surname><given-names>S.G.</given-names></name><name><surname>Yang</surname><given-names>W.M.</given-names></name><name><surname>Um</surname><given-names>J.Y.</given-names></name><name><surname>Chinnathambi</surname><given-names>A.</given-names></name><name><surname>Alharbi</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Ginkgolic Acid C 17:1, Derived from Ginkgo biloba Leaves, Suppresses Constitutive and Inducible STAT3 Activation through Induction of PTEN and SHP-1 Tyrosine Phosphatase</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>276</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22020276</pub-id></element-citation></ref><ref id="B50-ijms-21-09049"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Du</surname><given-names>W.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Kong</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Xiao</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name></person-group><article-title>Antitumor Effects of Ginkgolic Acid in Human Cancer Cell Occur via Cell Cycle Arrest and Decrease the Bcl-2/Bax Ratio to Induce Apoptosis</article-title><source>Chemotherapy</source><year>2010</year><volume>56</volume><fpage>393</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1159/000317750</pub-id><pub-id pub-id-type="pmid">20948210</pub-id></element-citation></ref><ref id="B51-ijms-21-09049"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>Q.</given-names></name><name><surname>Xue</surname><given-names>Y.</given-names></name><name><surname>Lv</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>D.</given-names></name><name><surname>Du</surname><given-names>J.</given-names></name><name><surname>Cai</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Gu</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name></person-group><article-title>Ginkgolic acids induce HepG2 cell death via a combination of apoptosis, autophagy and the mitochondrial pathway</article-title><source>Oncol. Lett.</source><year>2018</year><volume>15</volume><fpage>6400</fpage><lpage>6408</lpage><pub-id pub-id-type="doi">10.3892/ol.2018.8177</pub-id><?supplied-pmid 29725398?><pub-id pub-id-type="pmid">29725398</pub-id></element-citation></ref><ref id="B52-ijms-21-09049"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mango</surname><given-names>D.</given-names></name><name><surname>Weisz</surname><given-names>F.</given-names></name><name><surname>Nistic&#x000f2;</surname><given-names>R.</given-names></name></person-group><article-title>Ginkgolic Acid Protects against A&#x003b2;-Induced Synaptic Dysfunction in the Hippocampus</article-title><source>Front. Pharmacol.</source><year>2016</year><volume>7</volume><fpage>401</fpage><pub-id pub-id-type="doi">10.3389/fphar.2016.00401</pub-id><?supplied-pmid 27833555?><pub-id pub-id-type="pmid">27833555</pub-id></element-citation></ref><ref id="B53-ijms-21-09049"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>I.</given-names></name><name><surname>Ito</surname><given-names>A.</given-names></name><name><surname>Hirai</surname><given-names>G.</given-names></name><name><surname>Nishimura</surname><given-names>S.</given-names></name><name><surname>Kawasaki</surname><given-names>H.</given-names></name><name><surname>Saitoh</surname><given-names>H.</given-names></name><name><surname>Kimura</surname><given-names>K.I.</given-names></name><name><surname>Sodeoka</surname><given-names>M.</given-names></name><name><surname>Yoshida</surname><given-names>M.</given-names></name></person-group><article-title>Ginkgolic Acid Inhibits Protein SUMOylation by Blocking Formation of the E1-SUMO Intermediate</article-title><source>Chem. Biol.</source><year>2009</year><volume>16</volume><fpage>133</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2009.01.009</pub-id><?supplied-pmid 19246003?><pub-id pub-id-type="pmid">19246003</pub-id></element-citation></ref><ref id="B54-ijms-21-09049"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000fc;</surname><given-names>J.M.</given-names></name><name><surname>Yan</surname><given-names>S.</given-names></name><name><surname>Jamaluddin</surname><given-names>S.</given-names></name><name><surname>Weakley</surname><given-names>S.M.</given-names></name><name><surname>Liang</surname><given-names>Z.</given-names></name><name><surname>Siwak</surname><given-names>E.B.</given-names></name><name><surname>Yao</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name></person-group><article-title>Ginkgolic acid inhibits HIV protease activity and HIV infection in vitro</article-title><source>Med. Sci. Monit.</source><year>2012</year><volume>18</volume><fpage>293</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.12659/MSM.883261</pub-id><?supplied-pmid 22847190?><pub-id pub-id-type="pmid">22847190</pub-id></element-citation></ref><ref id="B55-ijms-21-09049"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borenstein</surname><given-names>R.</given-names></name><name><surname>Hanson</surname><given-names>B.A.</given-names></name><name><surname>Markosyan</surname><given-names>R.M.</given-names></name><name><surname>Gallo</surname><given-names>E.S.</given-names></name><name><surname>Narasipura</surname><given-names>S.D.</given-names></name><name><surname>Bhutta</surname><given-names>M.</given-names></name><name><surname>Shechter</surname><given-names>O.</given-names></name><name><surname>Lurain</surname><given-names>N.S.</given-names></name><name><surname>Cohen</surname><given-names>F.S.</given-names></name><name><surname>Al-Harthi</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Ginkgolic acid inhibits fusion of enveloped viruses</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>4746</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-61700-0</pub-id><?supplied-pmid 32179788?><pub-id pub-id-type="pmid">32179788</pub-id></element-citation></ref><ref id="B56-ijms-21-09049"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verhoeckx</surname><given-names>K.C.M.</given-names></name><name><surname>Korthout</surname><given-names>H.A.</given-names></name><name><surname>Van Meeteren-Kreikamp</surname><given-names>A.</given-names></name><name><surname>Ehlert</surname><given-names>K.A.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Van Der Greef</surname><given-names>J.</given-names></name><name><surname>Rodenburg</surname><given-names>R.J.T.</given-names></name><name><surname>Witkamp</surname><given-names>R.F.</given-names></name></person-group><article-title>Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways</article-title><source>Int. Immunopharmacol.</source><year>2006</year><volume>6</volume><fpage>656</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2005.10.002</pub-id><?supplied-pmid 16504929?><pub-id pub-id-type="pmid">16504929</pub-id></element-citation></ref><ref id="B57-ijms-21-09049"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruhaak</surname><given-names>L.R.</given-names></name><name><surname>Felth</surname><given-names>J.</given-names></name><name><surname>Karlsson</surname><given-names>P.C.</given-names></name><name><surname>Rafter</surname><given-names>J.J.</given-names></name><name><surname>Verpoorte</surname><given-names>R.</given-names></name><name><surname>Bohlin</surname><given-names>L.</given-names></name></person-group><article-title>Evaluation of the Cyclooxygenase Inhibiting Effects of Six Major Cannabinoids Isolated from Cannabis sativa</article-title><source>Biol. Pharm. Bull.</source><year>2011</year><volume>34</volume><fpage>774</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1248/bpb.34.774</pub-id><pub-id pub-id-type="pmid">21532172</pub-id></element-citation></ref><ref id="B58-ijms-21-09049"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nallathambi</surname><given-names>R.</given-names></name><name><surname>Mazuz</surname><given-names>M.</given-names></name><name><surname>Ion</surname><given-names>A.</given-names></name><name><surname>Selvaraj</surname><given-names>G.</given-names></name><name><surname>Weininger</surname><given-names>S.</given-names></name><name><surname>Fridlender</surname><given-names>M.</given-names></name><name><surname>Nasser</surname><given-names>A.</given-names></name><name><surname>Sagee</surname><given-names>O.</given-names></name><name><surname>Kumari</surname><given-names>P.</given-names></name><name><surname>Nemichenizer</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Anti-Inflammatory Activity in Colon Models Is Derived from &#x00394;9-Tetrahydrocannabinolic Acid That Interacts with Additional Compounds in Cannabis Extracts</article-title><source>Cannabis Cannabinoid Res.</source><year>2017</year><volume>2</volume><fpage>167</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1089/can.2017.0027</pub-id><pub-id pub-id-type="pmid">29082314</pub-id></element-citation></ref><ref id="B59-ijms-21-09049"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moldzio</surname><given-names>R.</given-names></name><name><surname>Pacher</surname><given-names>T.</given-names></name><name><surname>Krewenka</surname><given-names>C.</given-names></name><name><surname>Kranner</surname><given-names>B.</given-names></name><name><surname>Novak</surname><given-names>J.</given-names></name><name><surname>Duvigneau</surname><given-names>J.C.</given-names></name><name><surname>Rausch</surname><given-names>W.D.</given-names></name></person-group><article-title>Effects of cannabinoids &#x00394;(9)-tetrahydrocannabinol, &#x00394;(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures</article-title><source>Phytomedicine</source><year>2012</year><volume>19</volume><fpage>819</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2012.04.002</pub-id><pub-id pub-id-type="pmid">22571976</pub-id></element-citation></ref><ref id="B60-ijms-21-09049"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadal</surname><given-names>X.</given-names></name><name><surname>Del R&#x000ed;o</surname><given-names>C.</given-names></name><name><surname>Casano</surname><given-names>S.</given-names></name><name><surname>Palomares</surname><given-names>B.</given-names></name><name><surname>Ferreiro-Vera</surname><given-names>C.</given-names></name><name><surname>Navarrete</surname><given-names>C.</given-names></name><name><surname>S&#x000e1;nchez-Carnerero</surname><given-names>C.</given-names></name><name><surname>Cantarero</surname><given-names>I.</given-names></name><name><surname>Bellido</surname><given-names>M.L.</given-names></name><name><surname>Meyer</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Tetrahydrocannabinolic acid is a potent PPAR&#x003b3; agonist with neuroprotective activity</article-title><source>Br. J. Pharmacol.</source><year>2017</year><volume>174</volume><fpage>4263</fpage><lpage>4276</lpage><pub-id pub-id-type="doi">10.1111/bph.14019</pub-id><pub-id pub-id-type="pmid">28853159</pub-id></element-citation></ref><ref id="B61-ijms-21-09049"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ligresti</surname><given-names>A.</given-names></name><name><surname>Moriello</surname><given-names>A.S.</given-names></name><name><surname>Starowicz</surname><given-names>K.</given-names></name><name><surname>Matias</surname><given-names>I.</given-names></name><name><surname>Pisanti</surname><given-names>S.</given-names></name><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Laezza</surname><given-names>C.</given-names></name><name><surname>Portella</surname><given-names>G.</given-names></name><name><surname>Bifulco</surname><given-names>M.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name></person-group><article-title>Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2006</year><volume>318</volume><fpage>1375</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1124/jpet.106.105247</pub-id><?supplied-pmid 16728591?><pub-id pub-id-type="pmid">16728591</pub-id></element-citation></ref><ref id="B62-ijms-21-09049"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Ligresti</surname><given-names>A.</given-names></name><name><surname>Schiano Moriello</surname><given-names>A.</given-names></name><name><surname>Iappelli</surname><given-names>M.</given-names></name><name><surname>Verde</surname><given-names>R.</given-names></name><name><surname>Stott</surname><given-names>C.G.</given-names></name><name><surname>Cristino</surname><given-names>L.</given-names></name><name><surname>Orlando</surname><given-names>P.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name></person-group><article-title>Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: Pro-apoptotic effects and underlying mechanisms</article-title><source>Br. J. Pharmacol.</source><year>2013</year><volume>168</volume><fpage>79</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.02027.x</pub-id><?supplied-pmid 22594963?><pub-id pub-id-type="pmid">22594963</pub-id></element-citation></ref><ref id="B63-ijms-21-09049"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirao-Suzuki</surname><given-names>M.</given-names></name><name><surname>Takeda</surname><given-names>S.</given-names></name><name><surname>Koga</surname><given-names>T.</given-names></name><name><surname>Takiguchi</surname><given-names>M.</given-names></name><name><surname>Toda</surname><given-names>A.</given-names></name></person-group><article-title>Cannabidiolic acid dampens the expression of cyclooxygenase-2 in MDA-MB-231 breast cancer cells: Possible implication of the peroxisome proliferator-activated receptor &#x003b2;/&#x003b4; abrogation</article-title><source>J. Toxicol. Sci.</source><year>2020</year><volume>45</volume><fpage>227</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.2131/jts.45.227</pub-id><?supplied-pmid 32238697?><pub-id pub-id-type="pmid">32238697</pub-id></element-citation></ref><ref id="B64-ijms-21-09049"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>S.</given-names></name><name><surname>Okazaki</surname><given-names>H.</given-names></name><name><surname>Ikeda</surname><given-names>E.</given-names></name><name><surname>Abe</surname><given-names>S.</given-names></name><name><surname>Yoshioka</surname><given-names>Y.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Aramaki</surname><given-names>H.</given-names></name></person-group><article-title>Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells</article-title><source>J. Toxicol. Sci.</source><year>2014</year><volume>39</volume><fpage>711</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.2131/jts.39.711</pub-id><pub-id pub-id-type="pmid">25242400</pub-id></element-citation></ref><ref id="B65-ijms-21-09049"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>S.</given-names></name><name><surname>Okajima</surname><given-names>S.</given-names></name><name><surname>Miyoshi</surname><given-names>H.</given-names></name><name><surname>Yoshida</surname><given-names>K.</given-names></name><name><surname>Okamoto</surname><given-names>Y.</given-names></name><name><surname>Okada</surname><given-names>T.</given-names></name><name><surname>Amamoto</surname><given-names>T.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Omiecinski</surname><given-names>C.J.</given-names></name><name><surname>Aramaki</surname><given-names>H.</given-names></name></person-group><article-title>Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration</article-title><source>Toxicol. Lett.</source><year>2012</year><volume>214</volume><fpage>314</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2012.08.029</pub-id><pub-id pub-id-type="pmid">22963825</pub-id></element-citation></ref><ref id="B66-ijms-21-09049"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>M.</given-names></name><name><surname>Takeda</surname><given-names>S.</given-names></name><name><surname>Okazaki</surname><given-names>H.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Takiguchi</surname><given-names>M.</given-names></name><name><surname>Aramaki</surname><given-names>H.</given-names></name></person-group><article-title>Cannabidiolic Acid-Mediated Interference with AP-1 Transcriptional Activity in MDA-MB-231 Breast Cancer Cells</article-title><source>Nat. Prod. Commun.</source><year>2017</year><volume>12</volume><fpage>759</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1177/1934578X1701200520</pub-id><pub-id pub-id-type="pmid">30496661</pub-id></element-citation></ref><ref id="B67-ijms-21-09049"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Vellani</surname><given-names>V.</given-names></name><name><surname>Schiano-Moriello</surname><given-names>A.</given-names></name><name><surname>Marini</surname><given-names>P.</given-names></name><name><surname>Magherini</surname><given-names>P.C.</given-names></name><name><surname>Orlando</surname><given-names>P.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name></person-group><article-title>Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2008</year><volume>325</volume><fpage>1007</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1124/jpet.107.134809</pub-id><pub-id pub-id-type="pmid">18354058</pub-id></element-citation></ref><ref id="B68-ijms-21-09049"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>S.</given-names></name><name><surname>Misawa</surname><given-names>K.</given-names></name><name><surname>Yamamoto</surname><given-names>I.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name></person-group><article-title>Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in Cannabis</article-title><source>Drug Metab. Dispos.</source><year>2008</year><volume>36</volume><fpage>1917</fpage><lpage>1921</lpage><pub-id pub-id-type="doi">10.1124/dmd.108.020909</pub-id><pub-id pub-id-type="pmid">18556441</pub-id></element-citation></ref><ref id="B69-ijms-21-09049"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rock</surname><given-names>E.M.</given-names></name><name><surname>Limebeer</surname><given-names>C.L.</given-names></name><name><surname>Parker</surname><given-names>L.A.</given-names></name></person-group><article-title>Effect of cannabidiolic acid and &#x02206;9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain</article-title><source>Psychopharmacology</source><year>2018</year><volume>235</volume><fpage>3259</fpage><lpage>3271</lpage><pub-id pub-id-type="doi">10.1007/s00213-018-5034-1</pub-id><pub-id pub-id-type="pmid">30225659</pub-id></element-citation></ref><ref id="B70-ijms-21-09049"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rock</surname><given-names>E.M.</given-names></name><name><surname>Bolognini</surname><given-names>D.</given-names></name><name><surname>Limebeer</surname><given-names>C.L.</given-names></name><name><surname>Cascio</surname><given-names>M.G.</given-names></name><name><surname>Anavigoffer</surname><given-names>S.</given-names></name><name><surname>Fletcher</surname><given-names>P.J.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name><name><surname>Pertwee</surname><given-names>R.G.</given-names></name><name><surname>Parker</surname><given-names>L.A.</given-names></name></person-group><article-title>Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus</article-title><source>Br. J. Pharmacol.</source><year>2012</year><volume>165</volume><fpage>2620</fpage><lpage>2634</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01621.x</pub-id><pub-id pub-id-type="pmid">21827451</pub-id></element-citation></ref><ref id="B71-ijms-21-09049"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolognini</surname><given-names>D.</given-names></name><name><surname>Rock</surname><given-names>E.M.</given-names></name><name><surname>Cluny</surname><given-names>N.L.</given-names></name><name><surname>Cascio</surname><given-names>M.G.</given-names></name><name><surname>Limebeer</surname><given-names>C.L.</given-names></name><name><surname>Duncan</surname><given-names>M.</given-names></name><name><surname>Stott</surname><given-names>C.G.</given-names></name><name><surname>Javid</surname><given-names>F.A.</given-names></name><name><surname>Parker</surname><given-names>L.A.</given-names></name><name><surname>Pertwee</surname><given-names>R.G.</given-names></name></person-group><article-title>Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation</article-title><source>Br. J. Pharmacol.</source><year>2013</year><volume>168</volume><fpage>1456</fpage><lpage>1470</lpage><pub-id pub-id-type="doi">10.1111/bph.12043</pub-id><?supplied-pmid 23121618?><pub-id pub-id-type="pmid">23121618</pub-id></element-citation></ref><ref id="B72-ijms-21-09049"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>L.L.</given-names></name><name><surname>Low</surname><given-names>I.K.</given-names></name><name><surname>Banister</surname><given-names>S.D.</given-names></name><name><surname>McGregor</surname><given-names>I.S.</given-names></name><name><surname>Arnold</surname><given-names>J.C.</given-names></name></person-group><article-title>Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome</article-title><source>J. Nat. Prod.</source><year>2019</year><volume>82</volume><fpage>3047</fpage><lpage>3055</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.9b00600</pub-id><?supplied-pmid 31686510?><pub-id pub-id-type="pmid">31686510</pub-id></element-citation></ref><ref id="B73-ijms-21-09049"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehrke</surname><given-names>M.</given-names></name><name><surname>Lazar</surname><given-names>M.A.</given-names></name></person-group><article-title>The many faces of PPARgamma</article-title><source>Cell</source><year>2005</year><volume>123</volume><fpage>993</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.11.026</pub-id><?supplied-pmid 16360030?><pub-id pub-id-type="pmid">16360030</pub-id></element-citation></ref><ref id="B74-ijms-21-09049"><label>74.</label><element-citation publication-type="journal"><article-title>Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980&#x02013;2015: A systematic analysis for the Global Burden of Disease Study 2015</article-title><source>Lancet</source><year>2016</year><volume>388</volume><fpage>1459</fpage><lpage>1544</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)31012-1</pub-id><pub-id pub-id-type="pmid">27733281</pub-id></element-citation></ref><ref id="B75-ijms-21-09049"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sciacovelli</surname><given-names>M.</given-names></name><name><surname>Schmidt</surname><given-names>C.</given-names></name><name><surname>Maher</surname><given-names>E.R.</given-names></name><name><surname>Frezza</surname><given-names>C.</given-names></name></person-group><article-title>Metabolic Drivers in Hereditary Cancer Syndromes</article-title><source>Annu. Rev. Cancer Biol.</source><year>2020</year><volume>4</volume><fpage>77</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1146/annurev-cancerbio-030419-033612</pub-id></element-citation></ref><ref id="B76-ijms-21-09049"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shekhar</surname><given-names>M.P.</given-names></name></person-group><article-title>Drug resistance: Challenges to effective therapy</article-title><source>Curr. Cancer Drug Targets</source><year>2011</year><volume>11</volume><fpage>613</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.2174/156800911795655921</pub-id><pub-id pub-id-type="pmid">21486215</pub-id></element-citation></ref><ref id="B77-ijms-21-09049"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.W.H.</given-names></name><name><surname>Vederas</surname><given-names>J.C.</given-names></name></person-group><article-title>Drug Discovery and Natural Products: End of an Era or an Endless Frontier?</article-title><source>Science</source><year>2009</year><volume>325</volume><fpage>161</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1126/science.1168243</pub-id><pub-id pub-id-type="pmid">19589993</pub-id></element-citation></ref><ref id="B78-ijms-21-09049"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>D.J.</given-names></name><name><surname>Cragg</surname><given-names>G.M.</given-names></name></person-group><article-title>Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010</article-title><source>J. Nat. Prod.</source><year>2012</year><volume>75</volume><fpage>311</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1021/np200906s</pub-id><pub-id pub-id-type="pmid">22316239</pub-id></element-citation></ref><ref id="B79-ijms-21-09049"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricote</surname><given-names>M.</given-names></name><name><surname>Glass</surname><given-names>C.K.</given-names></name></person-group><article-title>PPARs and molecular mechanisms of transrepression</article-title><source>Biochim. Biophys. Acta (BBA) Mol. Cell Biol. Lipids</source><year>2007</year><volume>1771</volume><fpage>926</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2007.02.013</pub-id></element-citation></ref><ref id="B80-ijms-21-09049"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascual</surname><given-names>G.</given-names></name><name><surname>Fong</surname><given-names>A.L.</given-names></name><name><surname>Ogawa</surname><given-names>S.</given-names></name><name><surname>Gamliel</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>A.C.</given-names></name><name><surname>Perissi</surname><given-names>V.</given-names></name><name><surname>Rose</surname><given-names>D.W.</given-names></name><name><surname>Willson</surname><given-names>T.M.</given-names></name><name><surname>Rosenfeld</surname><given-names>M.G.</given-names></name><name><surname>Glass</surname><given-names>C.K.</given-names></name></person-group><article-title>A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma</article-title><source>Nature</source><year>2005</year><volume>437</volume><fpage>759</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1038/nature03988</pub-id><pub-id pub-id-type="pmid">16127449</pub-id></element-citation></ref><ref id="B81-ijms-21-09049"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>Y.</given-names></name><name><surname>Moreau</surname><given-names>F.</given-names></name><name><surname>Chadee</surname><given-names>K.</given-names></name></person-group><article-title>PPAR&#x003b3; is an E3 ligase that induces the degradation of NF&#x003ba;B/p65</article-title><source>Nat. Commun.</source><year>2012</year><volume>3</volume><fpage>1300</fpage><pub-id pub-id-type="doi">10.1038/ncomms2270</pub-id><?supplied-pmid 23250430?><pub-id pub-id-type="pmid">23250430</pub-id></element-citation></ref><ref id="B82-ijms-21-09049"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C.C.</given-names></name><name><surname>Du</surname><given-names>W.</given-names></name><name><surname>Wen</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>J.Y.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name></person-group><article-title>Effects of natural plant ginkgolic acids on the apoptosis of human Hep-2 cancer cells</article-title><source>Sichuan Da Xue Xue Bao. Yi Xue Ban (J. Sichuan Univ. Med. Sci. Ed.)</source><year>2009</year><volume>40</volume><fpage>459</fpage><lpage>461</lpage></element-citation></ref><ref id="B83-ijms-21-09049"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerstmeier</surname><given-names>J.</given-names></name><name><surname>Seegers</surname><given-names>J.</given-names></name><name><surname>Witt</surname><given-names>F.</given-names></name><name><surname>Waltenberger</surname><given-names>B.</given-names></name><name><surname>Temml</surname><given-names>V.</given-names></name><name><surname>Rollinger</surname><given-names>J.</given-names></name><name><surname>Stuppneret</surname><given-names>H.</given-names></name><name><surname>Koeberle</surname><given-names>A.</given-names></name><name><surname>Schuster</surname><given-names>D.</given-names></name><name><surname>Werz</surname><given-names>O.</given-names></name></person-group><article-title>Ginkgolic Acid is a Multi-Target Inhibitor of Key Enzymes in Pro-Inflammatory Lipid Mediator Biosynthesis</article-title><source>Front. Pharmacol.</source><year>2019</year><volume>10</volume><fpage>797</fpage><pub-id pub-id-type="doi">10.3389/fphar.2019.00797</pub-id><?supplied-pmid 31379572?><pub-id pub-id-type="pmid">31379572</pub-id></element-citation></ref><ref id="B84-ijms-21-09049"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Tang</surname><given-names>Z.</given-names></name><name><surname>Cao</surname><given-names>F.</given-names></name></person-group><article-title>The antibacterial activity and mechanism of ginkgolic acid C15:1</article-title><source>BMC Biotechnol.</source><year>2017</year><volume>17</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/s12896-016-0324-3</pub-id><?supplied-pmid 28088196?><pub-id pub-id-type="pmid">28056928</pub-id></element-citation></ref><ref id="B85-ijms-21-09049"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>C.</given-names></name><name><surname>Firestone</surname><given-names>G.L.</given-names></name><name><surname>Bjeldanes</surname><given-names>L.F.</given-names></name></person-group><article-title>Bcl-2 family-mediated apoptotic effects of 3,3&#x02032;-diindolylmethane (DIM) in human breast cancer cells</article-title><source>Biochem. Pharmacol.</source><year>2002</year><volume>63</volume><fpage>1085</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1016/S0006-2952(02)00856-0</pub-id><pub-id pub-id-type="pmid">11931841</pub-id></element-citation></ref><ref id="B86-ijms-21-09049"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wesche-Soldato</surname><given-names>D.E.</given-names></name><name><surname>Swan</surname><given-names>R.Z.</given-names></name><name><surname>Chung</surname><given-names>C.S.</given-names></name><name><surname>Ayala</surname><given-names>A.</given-names></name></person-group><article-title>The apoptotic pathway as a therapeutic target in sepsis</article-title><source>Curr. Drug Targets</source><year>2007</year><volume>8</volume><fpage>493</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.2174/138945007780362764</pub-id><pub-id pub-id-type="pmid">17430119</pub-id></element-citation></ref><ref id="B87-ijms-21-09049"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackey</surname><given-names>T.J.</given-names></name><name><surname>Borkowski</surname><given-names>A.</given-names></name><name><surname>Amin</surname><given-names>P.</given-names></name><name><surname>Jacobs</surname><given-names>S.C.</given-names></name><name><surname>Kyprianou</surname><given-names>N.</given-names></name></person-group><article-title>bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer</article-title><source>Urology</source><year>1998</year><volume>52</volume><fpage>1085</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1016/S0090-4295(98)00360-4</pub-id><pub-id pub-id-type="pmid">9836559</pub-id></element-citation></ref><ref id="B88-ijms-21-09049"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raisova</surname><given-names>M.</given-names></name><name><surname>Hossini</surname><given-names>A.M.</given-names></name><name><surname>Eberle</surname><given-names>J.</given-names></name><name><surname>Riebeling</surname><given-names>C.</given-names></name><name><surname>Orfanos</surname><given-names>C.E.</given-names></name><name><surname>Geilen</surname><given-names>C.C.</given-names></name><name><surname>Wieder</surname><given-names>T.</given-names></name><name><surname>Sturm</surname><given-names>I.</given-names></name><name><surname>Daniel</surname><given-names>P.T.</given-names></name></person-group><article-title>The Bax/Bcl-2 Ratio Determines the Susceptibility of Human Melanoma Cells to CD95/Fas-Mediated Apoptosis</article-title><source>J. Investig. Dermatol.</source><year>2001</year><volume>117</volume><fpage>333</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1046/j.0022-202x.2001.01409.x</pub-id><pub-id pub-id-type="pmid">11511312</pub-id></element-citation></ref><ref id="B89-ijms-21-09049"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lohmann</surname><given-names>C.M.</given-names></name><name><surname>League</surname><given-names>A.A.</given-names></name><name><surname>Clark</surname><given-names>W.S.</given-names></name><name><surname>Lawson</surname><given-names>D.</given-names></name><name><surname>Derose</surname><given-names>P.B.</given-names></name><name><surname>Cohen</surname><given-names>C.</given-names></name></person-group><article-title>Bcl-2: Bax and Bcl-2: Bcl-x ratios by image cytometric quantitation of immunohistochemical expression in ovarian carcinoma: Correlation with prognosis</article-title><source>Cytometry</source><year>2000</year><volume>42</volume><fpage>61</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0320(20000215)42:1&#x0003c;61::AID-CYTO9&#x0003e;3.0.CO;2-5</pub-id><pub-id pub-id-type="pmid">10679744</pub-id></element-citation></ref><ref id="B90-ijms-21-09049"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catlett-Falcone</surname><given-names>R.</given-names></name><name><surname>Landowski</surname><given-names>T.H.</given-names></name><name><surname>Oshiro</surname><given-names>M.M.</given-names></name><name><surname>Turkson</surname><given-names>J.</given-names></name><name><surname>Levitzki</surname><given-names>A.</given-names></name><name><surname>Savino</surname><given-names>R.</given-names></name><name><surname>Ciliberto</surname><given-names>G.</given-names></name><name><surname>Moscinski</surname><given-names>L.</given-names></name><name><surname>Fern&#x000e1;ndez-Luna</surname><given-names>J.L.</given-names></name><name><surname>Nu&#x000f1;ez</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells</article-title><source>Immunology</source><year>1999</year><volume>10</volume><fpage>105</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80011-4</pub-id></element-citation></ref><ref id="B91-ijms-21-09049"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bharti</surname><given-names>A.C.</given-names></name><name><surname>Donato</surname><given-names>N.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Curcumin (Diferuloylmethane) Inhibits Constitutive and IL-6-Inducible STAT3 Phosphorylation in Human Multiple Myeloma Cells</article-title><source>J. Immunol.</source><year>2003</year><volume>171</volume><fpage>3863</fpage><lpage>3871</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.7.3863</pub-id><pub-id pub-id-type="pmid">14500688</pub-id></element-citation></ref><ref id="B92-ijms-21-09049"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Crowe</surname><given-names>P.J.</given-names></name><name><surname>Goldstein</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>J.L.</given-names></name></person-group><article-title>STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review)</article-title><source>Int. J. Oncol.</source><year>2012</year><volume>41</volume><fpage>1181</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.3892/ijo.2012.1568</pub-id><pub-id pub-id-type="pmid">22842992</pub-id></element-citation></ref><ref id="B93-ijms-21-09049"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinrich</surname><given-names>P.C.</given-names></name><name><surname>Behrmann</surname><given-names>I.</given-names></name><name><surname>Haan</surname><given-names>S.</given-names></name><name><surname>Hermanns</surname><given-names>H.M.</given-names></name><name><surname>M&#x000fc;ller-Newen</surname><given-names>G.</given-names></name><name><surname>Schaper</surname><given-names>F.</given-names></name></person-group><article-title>Principles of interleukin (IL)-6-type cytokine signalling and its regulation</article-title><source>Biochem. J.</source><year>2003</year><volume>374</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1042/bj20030407</pub-id><?supplied-pmid 12773095?><pub-id pub-id-type="pmid">12773095</pub-id></element-citation></ref><ref id="B94-ijms-21-09049"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodge</surname><given-names>D.R.</given-names></name><name><surname>Hurt</surname><given-names>E.M.</given-names></name><name><surname>Farrar</surname><given-names>W.L.</given-names></name></person-group><article-title>The role of IL-6 and STAT3 in inflammation and cancer</article-title><source>Eur. J. Cancer</source><year>2005</year><volume>41</volume><fpage>2502</fpage><lpage>2512</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2005.08.016</pub-id><?supplied-pmid 16199153?><pub-id pub-id-type="pmid">16199153</pub-id></element-citation></ref><ref id="B95-ijms-21-09049"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Steinberg</surname><given-names>B.M.</given-names></name></person-group><article-title>PTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells</article-title><source>J. Gen. Virol.</source><year>2002</year><volume>83</volume><fpage>1651</fpage><lpage>1658</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-83-7-1651</pub-id><pub-id pub-id-type="pmid">12075083</pub-id></element-citation></ref><ref id="B96-ijms-21-09049"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Amin</surname><given-names>H.M.</given-names></name><name><surname>Franko</surname><given-names>B.</given-names></name><name><surname>Frantz</surname><given-names>C.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Lai</surname><given-names>R.</given-names></name></person-group><article-title>Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma</article-title><source>Blood</source><year>2006</year><volume>108</volume><fpage>2796</fpage><lpage>2803</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-04-017434</pub-id><?supplied-pmid 16825495?><pub-id pub-id-type="pmid">16825495</pub-id></element-citation></ref><ref id="B97-ijms-21-09049"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorval</surname><given-names>V.</given-names></name><name><surname>Fraser</surname><given-names>P.E.</given-names></name></person-group><article-title>SUMO on the road to neurodegeneration</article-title><source>Biochim. Biophys. Acta (BBA) Bioenerg.</source><year>2007</year><volume>1773</volume><fpage>694</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2007.03.017</pub-id><?supplied-pmid 17475350?><pub-id pub-id-type="pmid">17475350</pub-id></element-citation></ref><ref id="B98-ijms-21-09049"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>P.M.</given-names></name><name><surname>Hayashi</surname><given-names>K.M.</given-names></name><name><surname>de Zubicaray</surname><given-names>G.</given-names></name><name><surname>Janke</surname><given-names>A.L.</given-names></name><name><surname>Rose</surname><given-names>S.E.</given-names></name><name><surname>Semple</surname><given-names>J.</given-names></name><name><surname>Herman</surname><given-names>D.</given-names></name><name><surname>Hong</surname><given-names>M.S.</given-names></name><name><surname>Dittmer</surname><given-names>S.S.</given-names></name><name><surname>Doddrell</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>Dynamics of gray matter loss in Alzheimer&#x02019;s disease</article-title><source>J. Neurosci.</source><year>2003</year><volume>23</volume><fpage>994</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-03-00994.2003</pub-id><?supplied-pmid 12574429?><pub-id pub-id-type="pmid">12574429</pub-id></element-citation></ref><ref id="B99-ijms-21-09049"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arendt</surname><given-names>T.</given-names></name></person-group><article-title>Synaptic degeneration in Alzheimer&#x02019;s disease</article-title><source>Acta Neuropathol.</source><year>2009</year><volume>118</volume><fpage>167</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1007/s00401-009-0536-x</pub-id><?supplied-pmid 19390859?><pub-id pub-id-type="pmid">19390859</pub-id></element-citation></ref><ref id="B100-ijms-21-09049"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname><given-names>S.G.</given-names></name><name><surname>Smith</surname><given-names>M.</given-names></name><name><surname>Holodniy</surname><given-names>M.</given-names></name><name><surname>O Kahn</surname><given-names>J.</given-names></name></person-group><article-title>HIV-1 protease inhibitors. A review for clinicians</article-title><source>JAMA</source><year>1997</year><volume>277</volume><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1001/jama.1997.03540260059037</pub-id><?supplied-pmid 8990341?><pub-id pub-id-type="pmid">8990341</pub-id></element-citation></ref><ref id="B101-ijms-21-09049"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Formato</surname><given-names>M.</given-names></name><name><surname>Crescente</surname><given-names>G.</given-names></name><name><surname>Scognamiglio</surname><given-names>M.</given-names></name><name><surname>Fiorentino</surname><given-names>A.</given-names></name><name><surname>Pecoraro</surname><given-names>M.T.</given-names></name><name><surname>Piccolella</surname><given-names>S.</given-names></name><name><surname>Catauro</surname><given-names>M.</given-names></name><name><surname>Pacifico</surname><given-names>S.</given-names></name></person-group><article-title>(&#x02013;)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>2638</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25112638</pub-id><?supplied-pmid 32517131?><pub-id pub-id-type="pmid">32517131</pub-id></element-citation></ref><ref id="B102-ijms-21-09049"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>T.W.</given-names></name><name><surname>Lane</surname><given-names>B.</given-names></name><name><surname>Newton</surname><given-names>C.A.</given-names></name><name><surname>Friedman</surname><given-names>H.</given-names></name></person-group><article-title>The cannabinoid system and cytokine network</article-title><source>Proc. Soc. Exp. Biol. Med.</source><year>2000</year><volume>225</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1046/j.1525-1373.2000.22501.x</pub-id><?supplied-pmid 10998193?><pub-id pub-id-type="pmid">10998193</pub-id></element-citation></ref><ref id="B103-ijms-21-09049"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bidaut-Russell</surname><given-names>M.</given-names></name><name><surname>DeVane</surname><given-names>W.A.</given-names></name><name><surname>Howlett</surname><given-names>A.C.</given-names></name></person-group><article-title>Cannabinoid Receptors and Modulation of Cyclic AMP Accumulation in the Rat Brain</article-title><source>J. Neurochem.</source><year>1990</year><volume>55</volume><fpage>21</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1990.tb08815.x</pub-id><?supplied-pmid 2162376?><pub-id pub-id-type="pmid">2162376</pub-id></element-citation></ref><ref id="B104-ijms-21-09049"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herring</surname><given-names>A.C.</given-names></name><name><surname>Kaminski</surname><given-names>N.E.</given-names></name></person-group><article-title>Cannabinol-mediated inhibition of nuclear factor-kappaB, cAMP response element-binding protein, and interleukin-2 secretion by activated thymocytes</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1999</year><volume>291</volume><fpage>1156</fpage><lpage>1163</lpage><pub-id pub-id-type="pmid">10565837</pub-id></element-citation></ref><ref id="B105-ijms-21-09049"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonhaus</surname><given-names>D.W.</given-names></name><name><surname>Chang</surname><given-names>L.K.</given-names></name><name><surname>Kwan</surname><given-names>J.</given-names></name><name><surname>Martin</surname><given-names>G.R.</given-names></name></person-group><article-title>Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: Evidence for agonist-specific trafficking of intracellular responses</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1998</year><volume>287</volume><fpage>884</fpage><lpage>888</lpage><?supplied-pmid 9864268?><pub-id pub-id-type="pmid">9864268</pub-id></element-citation></ref><ref id="B106-ijms-21-09049"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>T.W.</given-names></name><name><surname>Newton</surname><given-names>C.A.</given-names></name><name><surname>Friedman</surname><given-names>H.</given-names></name></person-group><article-title>Cannabinoids and the immune system</article-title><source>Pain Res. Manag.</source><year>2001</year><volume>6</volume><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1155/2001/326867</pub-id><?supplied-pmid 11854771?><pub-id pub-id-type="pmid">11854771</pub-id></element-citation></ref><ref id="B107-ijms-21-09049"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grotenhermen</surname><given-names>F.</given-names></name></person-group><article-title>Pharmacokinetics and Pharmacodynamics of Cannabinoids</article-title><source>Clin. Pharmacokinet.</source><year>2003</year><volume>42</volume><fpage>327</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.2165/00003088-200342040-00003</pub-id><pub-id pub-id-type="pmid">12648025</pub-id></element-citation></ref><ref id="B108-ijms-21-09049"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiley</surname><given-names>J.L.</given-names></name><name><surname>Martin</surname><given-names>B.R.</given-names></name></person-group><article-title>Cannabinoid pharmacology: Implications for additional cannabinoid receptor subtypes</article-title><source>Chem. Phys. Lipids</source><year>2002</year><volume>121</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/S0009-3084(02)00146-9</pub-id><pub-id pub-id-type="pmid">12505690</pub-id></element-citation></ref><ref id="B109-ijms-21-09049"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>N.L.</given-names></name><name><surname>Murphy</surname><given-names>A.J.</given-names></name><name><surname>England</surname><given-names>T.J.</given-names></name><name><surname>O&#x02019;Sullivan</surname><given-names>S.E.</given-names></name></person-group><article-title>A systematic review of minor phytocannabinoids with promising neuroprotective potential</article-title><source>Br. J. Pharmacol.</source><year>2020</year><volume>177</volume><fpage>4330</fpage><lpage>4352</lpage><pub-id pub-id-type="doi">10.1111/bph.15185</pub-id><?supplied-pmid 32608035?><pub-id pub-id-type="pmid">32608035</pub-id></element-citation></ref><ref id="B110-ijms-21-09049"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000ed;os</surname><given-names>J.L.</given-names></name><name><surname>Francini</surname><given-names>F.</given-names></name><name><surname>Schinella</surname><given-names>G.R.</given-names></name></person-group><article-title>Natural Products for the Treatment of Type 2 Diabetes Mellitus</article-title><source>Planta Med.</source><year>2015</year><volume>81</volume><fpage>975</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1055/s-0035-1546131</pub-id><?supplied-pmid 26132858?><pub-id pub-id-type="pmid">26132858</pub-id></element-citation></ref><ref id="B111-ijms-21-09049"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauli</surname><given-names>C.S.</given-names></name><name><surname>Conroy</surname><given-names>M.</given-names></name><name><surname>Heuvel</surname><given-names>B.D.V.</given-names></name><name><surname>Park</surname><given-names>S.H.</given-names></name></person-group><article-title>Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects</article-title><source>Front. Pharmacol.</source><year>2020</year><volume>11</volume><fpage>63</fpage><pub-id pub-id-type="doi">10.3389/fphar.2020.00063</pub-id><?supplied-pmid 32161538?><pub-id pub-id-type="pmid">32161538</pub-id></element-citation></ref><ref id="B112-ijms-21-09049"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>M.</given-names></name><name><surname>Robertson</surname><given-names>A.A.B.</given-names></name><name><surname>Cooper</surname><given-names>M.A.</given-names></name></person-group><article-title>Natural product and natural product derived drugs in clinical trials</article-title><source>Nat. Prod. Rep.</source><year>2014</year><volume>31</volume><fpage>1612</fpage><lpage>1661</lpage><pub-id pub-id-type="doi">10.1039/C4NP00064A</pub-id><?supplied-pmid 25204227?><pub-id pub-id-type="pmid">25204227</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijms-21-09049-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Chemical structures of our focused natural salicylates. Distinct phenyl moieties are contained in amorfrutins (A, B and C), THCA and CBDA, whereas fatty acids-based residues are contained in amorfrutins (A, B and C), gingkolic acid, grifolic acids, THCA and CBDA.</p></caption><graphic xlink:href="ijms-21-09049-g001"/></fig><table-wrap id="ijms-21-09049-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-21-09049-t001_Table 1</object-id><label>Table 1</label><caption><p>Salicylates with their structures and targeted protein.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Salicylates &#x00026; Structure</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Proteins</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Salicylic acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ferrochelatase (FECH)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B16-ijms-21-09049" ref-type="bibr">16</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<inline-graphic xlink:href="ijms-21-09049-i001.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cyclin-dependent kinase 2 (CDK2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B14-ijms-21-09049" ref-type="bibr">14</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b1;-Enolase (ENO1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B20-ijms-21-09049" ref-type="bibr">20</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pyruvate kinase isozyme M2 (PKM2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B20-ijms-21-09049" ref-type="bibr">20</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acetylsalicylic acid (Aspirin)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cyclooxygenase-1 (COX-1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-ijms-21-09049" ref-type="bibr">21</xref>,<xref rid="B22-ijms-21-09049" ref-type="bibr">22</xref>]</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<inline-graphic xlink:href="ijms-21-09049-i002.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cyclooxygenase-2 (COX-2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B18-ijms-21-09049" ref-type="bibr">18</xref>,<xref rid="B21-ijms-21-09049" ref-type="bibr">21</xref>,<xref rid="B22-ijms-21-09049" ref-type="bibr">22</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nuclear factor-kappaB (NF-&#x003ba;B)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B11-ijms-21-09049" ref-type="bibr">11</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cathepsin A (CTSA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B12-ijms-21-09049" ref-type="bibr">12</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibitor of nuclear factorkappa-B kinase subunit beta (I&#x003ba;&#x003ba;-&#x003b2;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-ijms-21-09049" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ribosomal S6 kinase 2 (RSK2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B13-ijms-21-09049" ref-type="bibr">13</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cyclin-dependent kinase 2 (CDK2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B14-ijms-21-09049" ref-type="bibr">14</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5-aminosalicylic acid (Mesalazine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arachidonate 5-lipoxygenase (ALOX5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B15-ijms-21-09049" ref-type="bibr">15</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ijms-21-09049-i003.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B16-ijms-21-09049" ref-type="bibr">16</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-(2-hydroxybenzoyl) oxybenzoic acid (Salsalate)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Acetyltransferase p300 (P300)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B24-ijms-21-09049" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ijms-21-09049-i004.jpg"/>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acetyl 3-aminoethyl salicylic acid (Ac3AESA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B16-ijms-21-09049" ref-type="bibr">16</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ijms-21-09049-i005.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High mobility group box 1 (HMGB1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B19-ijms-21-09049" ref-type="bibr">19</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-hydroxy-5-[(E)-2-{4-[(pyridin-2-yl) sulfamoyl] phenyl} diazen-1-yl] benzoic acid (Sulfasalazine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor necrosis factor alpha (TNF&#x003b1;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B17-ijms-21-09049" ref-type="bibr">17</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ijms-21-09049-i006.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arachidonate 5-lipoxygenase (ALOX5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B15-ijms-21-09049" ref-type="bibr">15</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium salicylate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cyclooxygenase-2 (COX-2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B18-ijms-21-09049" ref-type="bibr">18</xref>,<xref rid="B21-ijms-21-09049" ref-type="bibr">21</xref>,<xref rid="B22-ijms-21-09049" ref-type="bibr">22</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<inline-graphic xlink:href="ijms-21-09049-i007.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nuclear factor-kappaB(NF-&#x003ba;B)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B11-ijms-21-09049" ref-type="bibr">11</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibitor of nuclear factorkappa-B kinase subunit beta (I&#x003ba;&#x003ba;-&#x003b2;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-ijms-21-09049" ref-type="bibr">23</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="ijms-21-09049-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-21-09049-t002_Table 2</object-id><label>Table 2</label><caption><p>Source, biological activities, and mechanism of action of our focused natural salicylates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Natural Salicylates</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Source</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Biological Activity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism of Action</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Amorfrutins</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>A. fruticosa</italic> L. (bastard indigo), <italic>G. foetida</italic> Desf. (licorice)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antidiabetic</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of insulin resistance formation, dyslipidemia, liver steatosis, and induction of PPAR&#x003b3; ser273 phosphorylation by HFD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-ijms-21-09049" ref-type="bibr">40</xref>,<xref rid="B41-ijms-21-09049" ref-type="bibr">41</xref>,<xref rid="B43-ijms-21-09049" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anticancer</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Formation of reactive oxygen species, DNA fragmentation, caspase activation, phosphatidylserine externalization, and PARP cleavage induced apoptosis in colorectal cancer cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-ijms-21-09049" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-inflammatory</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lowering the expression of various inflammatory genes such as COX-2, GRO-&#x003b1;, IL-8, and MIP-3&#x003b1; in TNF-&#x003b1;- stimulated colon cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-ijms-21-09049" ref-type="bibr">42</xref>]</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ginkgolic acids</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>G. biloba</italic> L.</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Anticancer</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of the proliferation of renal cell carcinoma (RCC) cell lines 786-O and A498 by inactivating epidermal growth factor receptor (EGFR) signaling pathway with the downregulation of p-Akt and p-Erk expression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B44-ijms-21-09049" ref-type="bibr">44</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of I&#x003ba;B&#x003b1; degradation and reduction of the activity of NF-&#x003ba;B in MCF-7 and MDA-MB 231 breast cancer cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-ijms-21-09049" ref-type="bibr">45</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of the PI3K/Akt/mTOR signaling pathway of lung cancer cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-ijms-21-09049" ref-type="bibr">46</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduction of the cell viability and prevention of the de novo lipogenesis of pancreatic cancer cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-ijms-21-09049" ref-type="bibr">47</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduction of proliferation, migration, and invasion of SW480 colon cancer cells. Stimulation of AMPK activation and decreasing the expression of invasion-associated proteins, such as (MMP)-2, (CXCR4) and uPA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-ijms-21-09049" ref-type="bibr">48</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppression of STAT3 phosphorylation and reduction of cell proliferation in multiple myeloma cancer cells. Upregulation of the expression of PTEN and SHP-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-ijms-21-09049" ref-type="bibr">49</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of the growth of human tongue squamous carcinoma cells. Reduction of the Bcl-2/Bax ratio and stimulation of caspase-3 activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-ijms-21-09049" ref-type="bibr">50</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition the cell proliferation and induction of cell death through a combination of apoptosis, autophagy, and the mitochondrial pathway in human hepatoblastoma HepG2 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-ijms-21-09049" ref-type="bibr">51</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Neuroprotective</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhancement of long-term potentiation (LTP) in the hippocampus, restoring the A&#x003b2;-mediated paired-pulse ratio (PPR) alteration and rescuing the A&#x003b2;-mediated change in excitatory neurotransmission in mice model.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-ijms-21-09049" ref-type="bibr">52</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of the formation of E1-SUMO intermediate in an in situ cell-based SUMOylation assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-ijms-21-09049" ref-type="bibr">53</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Antiviral</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of HIV protease activity of HIV-1SF162 infection in human peripheral blood mononuclear cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B54-ijms-21-09049" ref-type="bibr">54</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The inhibitory effect on the fusion of a variety of enveloped viruses, including ZIKV, HSV-1, HCMV HIV, EBOV, IAV and EBV, and a nonenveloped human adenovirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B55-ijms-21-09049" ref-type="bibr">55</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Grifolic acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>A. confluens</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antitumor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduction of cell viability by blocking NADH production and inhibiting MMP and ATP production on both GH3 cells and osteosarcoma cell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-ijms-21-09049" ref-type="bibr">30</xref>,<xref rid="B36-ijms-21-09049" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetrahydro-cannabinolic acid (THCA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. sativa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunomodulatory</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeting PC-PLC enzymatic activity in phospholipids metabolism and inhibition of tumor TNF-a release from LPS-activated U937 macrophages and peripheral blood macrophages</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B56-ijms-21-09049" ref-type="bibr">56</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-inflammatory</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition COX1 and COX2 expression, Reduction of prostaglandin production also inhibition MMP9 expression in colon cancer cell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-ijms-21-09049" ref-type="bibr">57</xref>,<xref rid="B58-ijms-21-09049" ref-type="bibr">58</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Neuroprotective</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduction of dopaminergic neurons degenerative effect of MPP+, increasing cell survival in mice mesencephalic cultures</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B59-ijms-21-09049" ref-type="bibr">59</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduction of degenerative effects of 3-NPA, through a PPAR&#x003b3;-dependent pathway in N2a cell and in vivo mice model</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B60-ijms-21-09049" ref-type="bibr">60</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antineoplastic</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of cell proliferation in the breast cancer cell and prostate carcinoma cell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B61-ijms-21-09049" ref-type="bibr">61</xref>,<xref rid="B62-ijms-21-09049" ref-type="bibr">62</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cannabidiolic acid (CBDA)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic>C. sativa</italic>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Anticancer</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of the transcriptional activities of both activator protein I (AP-I) and peroxisome proliferator-activated receptor PPAR&#x003b2;/&#x003b4; in breast cancer cell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B63-ijms-21-09049" ref-type="bibr">63</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of human breast cancer cell metastasis by suppressing COX2 and proto-oncogene c-Fos expression and upregulation of the expression of SHARP1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B64-ijms-21-09049" ref-type="bibr">64</xref>,<xref rid="B65-ijms-21-09049" ref-type="bibr">65</xref>,<xref rid="B66-ijms-21-09049" ref-type="bibr">66</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Anti-inflammatory</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stimulation of vanilloid 1 and ankyrin 1 transient receptor potential (TRP) channels (TRPV1 and TRPA1, respectively), and antagonize a receptor, the Transient Receptor Potential Cation Channel Subfamily M Member 8 (TRPM8) in HEK 293 cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B67-ijms-21-09049" ref-type="bibr">67</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Selective inhibition of COX2. Reduction of inflammation when intraperitoneally administered in a rodent model of carrageenan-induced acute inflammation in the rat hind paw.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B68-ijms-21-09049" ref-type="bibr">68</xref>,<xref rid="B69-ijms-21-09049" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiemetic</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induction 5-HT1A receptors activity in vivo in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-ijms-21-09049" ref-type="bibr">70</xref>,<xref rid="B71-ijms-21-09049" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anticonvulsant</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increasing the temperature threshold at which the Scn1aRX/+ mice had a generalized tonic-clonic seizure.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-ijms-21-09049" ref-type="bibr">72</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>